

# 2024 Analytical Treatment Interruption (ATI) Consensus Workshop

8-10 May 2024 · Trademark Hotel, Nairobi, Kenya

## PROGRAMME

BILL & MELINDA  
GATES *foundation*



National Institutes of Health  
*Turning Discovery Into Health*



**KARIBU KENYA**

# WELCOME NOTE

## DEAR COLLEAGUES

It is with great pleasure that we welcome you to the 2nd Consensus Workshop on Analytical Treatment Interruption in HIV Cure Trials, co-hosted by the Sub-Saharan African Network of TB/HIV Excellence (SANTHE) and the US Military HIV Research Program (MHRP).

This event brings together leading experts in HIV cure research from five continents, including community advocates, persons living with HIV, scientists, clinicians, and representatives of funding, regulatory, and industry organisations. Our scientific understanding of potential mechanisms of inducing HIV control has evolved in the five years since the first workshop in 2018 and so too have the designs of analytical treatment interruption (ATI) trials. These trials are including new types of interventions, looking for different types of endpoints, and are being executed in more diverse settings and populations to better reflect the demography of the HIV pandemic. It is time to reconsider guidance on study design elements such as inclusion criteria, the duration of treatment interruption, frequency of viral load monitoring, and criteria for antiretroviral treatment restart. There are also ongoing concerns about how to prevent HIV transmission during ATI and potential risks associated with prolonged viremia after rebound, particularly as study designs shift to allow longer ATIs. In addition, some considerations that were not fully considered in the original guidelines are becoming more critical to address, including the participation of paediatric populations in ATI trials. Over the next few days, we will discuss and vote on key issues with the aim of drafting an updated ATI Consensus Guideline to facilitate standardisation of ATIs in HIV cure trials to maximise the safety of participants and their sexual partners while also advancing the science that may someday lead to an HIV cure.

We thank you for your participation and look forward to a successful event!

*The Organising Committee*

### **Thumbi Ndung'u**

Sub-Saharan African Network for TB/HIV Research Excellence (SANTHE)/Africa Health Research Institute (AHRI)

### **Krista Dong**

Ragon Institute of MGH, MIT and Harvard

### **Victoria Kasproicz**

Sub-Saharan African Network for TB/HIV Research Excellence (SANTHE)/Africa Health Research Institute (AHRI)

### **Moses Supercharger Nsubuga**

Joint Adherent Brothers & Sisters Against AIDS (JABASA)

### **Steven Deeks**

University of California, San Francisco

### **Boris Juelg**

Ragon Institute of MGH, MIT and Harvard

### **Mark Cotton**

Stellenbosch University (SU)

### **Philip Goulder**

University of Oxford (UO)

### **Lydie Trautmann**

US Military HIV Research Program - Henry Jackson Foundation (MHRP-HJF)/Developing Leadership and Innovation in Viral Eradication Research (DELIVER)

### **Donn Colby**

US Military HIV Research Program - Henry Jackson Foundation (MHRP-HJF)

### **Trevor Crowell**

US Military HIV Research Program - Henry Jackson Foundation (MHRP-HJF)

### **Karine Dubé**

University of California, San Diego (UCSD)

### **Sharon Lewin**

The Peter Doherty Institute for Infection and Immunity

### **Randall Tressler**

National Institutes of Allergy and Infectious Disease (NIAID)/National Institutes of Health (NIH)

# CONTENTS

<b>WELCOME NOTE</b>	<b>1</b>
<b>PROGRAMME</b>	<b>3</b>
<b>BIOGRAPHIES</b>	<b>6</b>
<b>LOGISTICS</b>	<b>37</b>

# PROGRAMME

## PREPARATION FOR IMPLEMENTATION OF HIV CURE TRIALS INVOLVING ATIS IN LOW- AND MIDDLE-INCOME COUNTRIES

### WEDNESDAY 8TH MAY

An overview for those not familiar with HIV cure studies and for those interested in understanding the challenges of rolling out trials in different settings.

- 8.00am: Registration**
- 8.30am: Introduction to HIV cure** – *Wadzanai Samaneka, University of Zimbabwe Clinical Trials Research Centre and Marina Caskey, The Rockefeller University*
- 9.30am: Why a cure is important** - *Moses Supercharger, Joint Adherent Brothers & Sisters Against AIDS JABASA)*
- 10.00am: Issues in HIV cure trials** - *Sharon Lewin, The Peter Doherty Institute for Infection and Immunity*
- 10.30am: Tea break**
- 11.00am: Perspectives/Reflections on primary/Acute infection trials** - *Carlo Sacdalan, SEARCH Research Foundation*
- 11.30am: Enrolling young women in an ATI trial in South Africa** - *Krista Dong, Ragon Institute of MGH, MIT and Harvard*
- 12.00pm: Primer on paediatrics** - *Mark Cotton, Stellenbosch University (SU)*
- 12:15pm: Paediatric ATI studies** - *Louise Kuhn, Columbia University Irving Medical Center (CUIMC)*
- 12.30pm: HIV cure trials Q & A with panel: Moderator: Marina Caskey, The Rockefeller University; and Presenters above**
- 1.30pm: Lunch break**
- 2.30pm: ATI eligibility** - *Steven Deeks, University of California, San Francisco (UCSF)*
- 3.00pm: ATI design** - *Donn Colby, US Military HIV Research Program - Henry Jackson Foundation (MHRP-HJF)*
- 3.30pm: Participant considerations** - *Karine Dubé, University of California San Diego (UCSD) and Michael Louella, University of Washington*
- 4.00pm: ATI in paediatrics**  
**P1115** - *Deborah Persaud, Johns Hopkins University School of Medicine (JHUSM)*
- 4.30pm: Tea break**
- 5.00pm: Special moderated session I - issues around implementation of paediatrics ATI studies focusing on baby cure and P1115**  
Introduction: *Philip Goulder, University of Oxford*  
Moderator: *Gabriela Cromhout, University of KwaZulu-Natal (UKZN)*  
Panel: *Philip Goulder, University of Oxford; Nomonde Bengu, Umkhuseli/University of KwaZulu-Natal (UKZN)/Queen Nandi Regional Hospital (QNRH); ATI child/parent; Adeodata Kekitiinwa, Baylor College of Medicine Children's Foundation Uganda (Baylor Uganda); Violet Korutaro, Baylor College of Medicine Children's Foundation Uganda (Baylor Uganda); and Mutsa Bwakura-Dangarembizi, University of Zimbabwe.*
- 5.45pm: End**

## ATI CONSENSUS WORKSHOP - THURSDAY 9TH MAY & FRIDAY 10TH MAY

### DAY 1 - THURSDAY 9TH MAY

- 7.30am: Registration**
- 8.00am: Welcome and meeting overview** – *Thumbi Ndung’u, Sub-Saharan African Network for TB/HIV Research Excellence (SANTHE)/Africa Health Research Institute (AHRI)*
- 8.15am: Overview of ATI studies to date and key issues** – *Katharine Bar, University of Pennsylvania*
- 9.00am: Review of previous consensus statement** - *Boris Juelg, Ragon Institute of MGH, MIT and Harvard*
- 9.30am: Voices from the front lines**  
Results from the 2024 International ATI Interactive Webinar Series - *Matt Romo, US Military HIV Research Program - Henry Jackson Foundation (MHRP-HJF) and Karine Dubé, University of California San Diego (UCSD)*
- 10:15am: Tea break**
- 10.45am: Participant considerations**  
Moderator: *Michael Louella, University of Washington*  
Panel: *Karine Dubé, University of California San Diego (UCSD); Matt Romo, US Military HIV Research Program - Henry Jackson Foundation (MHRP-HJF); Moses Supercharger, Joint Adherent Brothers & Sisters Against AIDS (JABASA); and Udom Likhitwonnawut, Thailand National CAB*
- 12:15pm: Lunch break**
- 1:15pm: Voting on participant considerations** - *Karine Dubé, University of California San Diego (UCSD); Matt Romo, US Military HIV Research Program - Henry Jackson Foundation (MHRP-HJF), Annie Miall, Harvard University*
- 1.45pm: ATI eligibility**  
Moderator: *Steven Deeks, University of California, San Francisco (UCSF)*  
Panel: *Boris Juelg, Ragon Institute of MGH, MIT and Harvard; Trevor Crowell, US Military HIV Research Program - Henry Jackson Foundation (MHRP-HJF); Wadzanai Samaneka, University of Zimbabwe Clinical Trials Research Centre; Sarah Fidler, Imperial College London; Charity Wambui, Moi University Clinical Research Centre; Michael Peluso, University of California, San Francisco (UCSF); Marina Caskey, The Rockefeller University*
- 4:15pm: Tea break**
- 4.45pm: Voting on ATI eligibility** - *Steven Deeks, University of California, San Francisco (UCSF)*
- 5.15pm: Special moderated session II - FRESH GS-5445 trial**  
Moderator: *Michael Louella, University of Washington*  
Panel: *Thumbi Ndung’u, Sub-Saharan African Network for TB/HIV Research Excellence (SANTHE)/Africa Health Research Institute (AHRI); Krista Dong, Ragon Institute of MGH, MIT and Harvard; and ATI participant*
- 6:00pm: End**
- 7.00pm: Dinner**

## DAY 2 – FRIDAY 10TH MAY

- 8.00am:** **Welcome back, recap, and overview for Day 2** - Lydie Trautmann, *US Military HIV Research Program - Henry Jackson Foundation (MHRP-HJF)/Developing Leadership and Innovation in Viral Eradication Research (DELIVER)*
- 8:15am:** **ATI design**  
Moderator: Marina Caskey, *The Rockefeller University*  
Panel: Donn Colby, *US Military HIV Research Program - Henry Jackson Foundation (MHRP-HJF)*; Trevor Crowell, *US Military HIV Research Program - Henry Jackson Foundation (MHRP-HJF)*; Thumbi Ndung'u, *Sub-Saharan African Network for TB/HIV Research Excellence (SANTHE)/Africa Health Research Institute (AHRI)*; Carlo Sacdalan, *SEARCH Research Foundation*; and Udom Likhitwonnawut, *Thailand National CAB*
- 10:45am:** **Tea break**
- 11.15am:** **Voting on ATI design** - Donn Colby, *US Military HIV Research Program - Henry Jackson Foundation (MHRP-HJF)*
- 11.45pm:** **ATI in paediatrics I**  
Moderator: Mark Cotton, *Stellenbosch University (SU)*; Gareth Tudor-Williams, *Imperial College London*  
Panel: Roger Shapiro, *Harvard TH Chan School of Public Health*; Mutsa Dangarembizi, *University of Zimbabwe*; Gabriela Cromhout, *University of KwaZulu-Natal (UKZN)*
- 12.45pm:** **Lunch break**
- 1.45pm:** **ATI in paediatrics II**  
Moderator: Gareth Tudor-Williams, *Imperial College London*  
Panel: Moherndran Archary, *University of KwaZulu-Natal (UKZN)*; Adeodata Kekitiinwa, *Baylor College of Medicine Children's Foundation Uganda*; Louise Kuhn, *Columbia University Irving Medical Center*
- 3.15pm:** **Tea break**
- 3.45pm:** **Voting on ATI in paediatrics** - Mark Cotton, *Stellenbosch University (SU)*
- 4.15pm:** **Recap, discussion, remaining challenges, and next steps** - Sharon Lewin, *The Peter Doherty Institute for Infection and Immunity*
- 5.15pm:** **End**

# BIOGRAPHIES



## ABDULWASIU TIAMIYU

AbdulwasIU Tiamiyu is the Director of the Clinical Research Center HJFMRI Nigeria supporting the Emerging Infectious Disease Branch and US Military HIV Research Program of the Walter Reed Army Institute of Research. Tiamiyu received his medical education from the University of Ilorin, Ilorin and National Hospital, Abuja Nigeria, a Diploma in Tropical Medicine and Hygiene (DTM&H) from the Royal College of Physicians London, and some research training from the Harvard Medical School Postgraduate Medical Educational Program (PGME) – Global Clinical Scholar Research Training (GCSRT). Currently, he serves as an academic Editor of PLOS ONE Journal and Journal of Nigerian Infectious Disease Society. Tiamiyu has authored numerous publications describing observational studies in HIV (especially in key populations), Tuberculosis, Emerging Infectious Diseases – Lassa fever, Mpox, etc., and tropical diseases. Tiamiyu is a fellow of the National Postgraduate Medical College of Nigeria and Afro-ADVAC.



## ADEODATA KEKITIINWA

Adeodata Kekitiinwa is an Emeritus Associate Clinical Professor of Paediatrics at Baylor College of Medicine, Department of Paediatrics, Section of Retrovirology. Upon retirement as Executive Director (ED) of Baylor Foundation Uganda in July 2022, Kekitiinwa engaged in research focusing on cure and antiretroviral treatment strategies for children and adolescents. She is the Clinical Research Leader (CRL), IMPAACT P1115 & 2028 Investigator of Record, Chief Investigator and Principal Investigator for Breather Plus trial at Baylor Foundation Uganda Clinic.

During her tenure as ED, Kekitiinwa led a team that won and oversaw the implementation of grants of over \$228 million to provide comprehensive HIV prevention, care and treatment, maternal-newborn child and Adolescent Health, Global Health Security, Training, and Leadership including five 5-year PEPFAR/CDC grants. At the time of her exit as ED the programme provided HIV care to over 160,000 HIV-infected individuals and had reduced mother-to-child HIV Transmission rates to <3%.

She set up and grew the largest paediatric HIV clinical centre of excellence (COE) in Uganda from about 700 children to over 8000 clients currently and used the knowledge and skills acquired to support the creation of the National Paediatric and Adolescent HIV/ TB units at the Uganda Ministry of Health. These units provide strategic leadership to ensure all policies include children and adolescents' agenda; 94% of 1800 ART-accredited health facilities offer paediatric and adolescent services.

Kekitiinwa's other passion is in reducing maternal and neonatal mortality. She implemented the PEPFAR-funded "Saving Mothers Giving Life" project in 3 districts in the Rwenzori region that reduced institutional and community maternal mortality rates by 45% and 41% respectively while layering prevention of mother-to-child services onto the same platform.

Kekitiinwa established and grew the research directorate from zero to 12 clinical trials and overall, 47 studies. She initiated the ideology and invested in accrediting the COE lab by the College of American Pathologists to ensure quality comprehensive quality services in research and programmes. She currently leads the laboratory to get full accreditation to perform Division of AIDS (DAIDS) NIH-sponsored studies.

She previously served as a senior consultant Paediatrician at Mulago National Referral Hospital.

Kekitiinwa has co-authored over 71 Publications peer-reviewed publications. The complete list of her peer-reviewed publications can be accessed through the link below.

<https://www.pubfacts.com/author/Adeodata+Kekitiinwa/>

<https://www.medifind.com/doctors/adeodata-r-kekitiinwa/346418159/publications?page=1>

In late 2023, Kekitiinwa was selected globally to receive the PENTA (Paediatric European Network for Treatment of AIDS) Brighter Future Award (BFA). The BFA is a global celebration to recognise outstanding individuals and organisations making significant contributions to the health and well-being of mothers and children through innovative and collaborative approaches.





## **AMBER MOODLEY**

Amber Moodley is a Senior Clinical Project Manager at the Henry M Jackson Foundation under the US Military HIV Research Program (MHRP). Moodley has over 15 years of experience managing complex clinical trials in the US, East Africa, South Africa, and Southeast Asia. She has extensive working knowledge of clinical research from protocol development, study start-up, conduct and close-out activities. Moodley's previous experience includes managing the day-to-day operations of the FRESH Acute HIV Cohort study in Durban, South Africa.



## **ANNETTE RID**

Annette Rid is a bioethicist at the NIH Clinical Center, Department of Bioethics, and the NIH Fogarty International Center, Division of International Science Policy, Planning and Evaluation. She was previously cross-appointed with the NIAID Division of AIDS, where she participated in a project on partner protections in HIV cure-related trials involving analytical trial interruptions. Her research interests span research ethics, the ethics of health policy and clinical ethics.



## **ANNIE MIALL**

Annie Miall is a research fellow at the Ragon Institute of MGH, Harvard and MIT. She is currently working on a sociobehavioral research project at the FRESH Clinic in Durban, South Africa to better understand the experiences of women taking part in ATI Trials. In college, she majored in History and Science and Molecular and Cellular Biology at Harvard. Outside of her academic pursuits, Annie finds solace and joy in running and backpacking. Driven by a desire to make a meaningful impact on the world, Annie aspires to become a world-class physician, dedicated to serving vulnerable populations, striving to address disparities and improve access to essential services.



## **AUDE CHRISTELLE KA'E**

Aude Christelle ka'e has a master's degree in medical microbiology and a PhD in medical Virology. She is a Research-for-cure academy fellow alumni and member of the International AIDS Society. Currently she is a post post-doctoral researcher in the laboratory of virology at the Chantal Biya International Reference Centre for Research on HIV/AIDS Prevention and Management (CIRCB) where she is involved in virological monitoring of people living with HIV (viral load testing/interpretation and HIV-1 genotypic resistance testing and interpretation as well). She is also involved in a lab activity focusing on the characterisation of HIV-1 reservoirs among adolescents living with perinatally acquired HIV-1 where they are evaluating the quantitative and the genotypic profile of their viral reservoirs.



## **BEATRIZ GRINSZTEJN**

Beatriz Grinsztejn is an Infectious Diseases physician-scientist dedicated to HIV prevention and care for over 30 years. She is the Director of the FIOCRUZ STI/AIDS Prevention and Therapeutic Clinical Trials Unit at FIOCRUZ, which develops and implements prevention and therapeutic clinical trials and cohort studies. The unit is affiliated to the HIV Prevention Trials Network (HPTN), the Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (ACTG), the HIV Vaccine Trials Group (HVTN), the COVID-19 Prevention Network (CoVPN), and the ANRS.

Grinsztejn is the Brazilian PI for the Caribbean, Central and South America Network for HIV epidemiology - CCASAnet (a Regional Member of the International Epidemiologic Databases to Evaluate AIDS - IeDEA), for the NCI-funded US-Latin American-Caribbean HIV/HPV-Cancer Prevention Clinical Trials Network (ULACNet), and for the NICHD-funded PATC3H Network (Prevention and Treatment through a Comprehensive Care Continuum for HIV-affected Adolescents in Resource Constrained Settings). She is the Co-Chair of the HPTN 083 Study, which compared injectable cabotegravir to daily oral TDF/FTC for HIV pre-exposure prophylaxis in cisgender men and transgender women who have sex with men. She is the Chair of the ImPrEP CAB-LA implementation study, which will evaluate the implementation of CAB-LA among 1200 MSM and other sexual and gender minorities in Brazil. For several years, she received the Career Development Award by the Brazilian National Research Council (2006, 2009, 2013, 2016, 2019, 2022, 2024) and the Rio de Janeiro State Scientist award by the Carlos Chagas Filho Foundation for Research

Support of the State of Rio de Janeiro - FAPERJ (2007, 2009, 2012, 2015, 2018, 2021). She also received the HPTN Ward Cates Spirit Award in 2021 and the ACTG James Hakim Award in 2022. In 2022 she was awarded to present the N’Gail-Mann Lecture at CROI. She is the current International AIDS Society (IAS) President-elect.



## **BORIS JUELG**

Boris Juelg is an Associate Professor of Medicine at Harvard Medical School and a physician in the Division of Infectious Diseases at Massachusetts General Hospital (MGH). He is a Member of the Ragon Institute of Mass General, MIT and Harvard.

As a physician-scientist, Juelg aims to link preclinical and clinical studies to identify and test the most promising immunological strategies to prevent and treat HIV infection. He is specifically interested in evaluating passive and active immunisation approaches using broadly neutralising antibodies and novel vaccine candidates. Juelg is conducting phase I/II clinical trials that are testing such concepts and translating findings from the lab into the clinic. He serves as the director for the MGH ID Clinical Research Unit and as a member of the executive committee of the Harvard Centre for AIDS Research.

Juelg received an MD and PhD from Christian Albrecht University in Kiel, Germany. He completed a postdoctoral research fellowship with Dr Bruce Walker before undergoing internal medicine training at MGH and a fellowship in infectious diseases through the combined programme at MGH and Brigham and Women’s Hospital.



## **BRAD JONES**

Brad Jones is a Viral Immunologist and an Associate Professor at Weill Cornell Medical College in the Division of Infectious Diseases with a cross-appointment in the Department of Microbiology and Immunology. He received his PhD in Immunology from the University of Toronto before beginning a post-doctoral fellowship at the Ragon Institute of MGH, MIT, and Harvard in 2012. He currently serves as Principal Investigator of the \$28 million Research Enterprise to Advance a Cure for HIV (REACH), one of the NIH’s flagship ‘Martin Delaney Collaboratories’. Jones is on the Steering Committee of the Global Scientific Strategy for an HIV Cure initiative of the International AIDS Society (IAS), co-Chairs the IAS Advocacy-for-Cure Academy- which focuses on raising awareness on the state of HIV cure research in the global South, and is the Track A Lead for ‘AIDS 2022’, the 24th International AIDS Conference.



## **BRIAN DOEHLE**

Brian Doehle is a Senior Programme Officer on the Accelerator Team, within the Global Health division at the Bill & Melinda Gates Foundation. His career has been dedicated to the development of therapies for those experiencing viral and inflammatory diseases, including HIV, HCV, HBV, Influenza, SARS-CoV-2 and autoimmune disease. Prior to re-joining the Bill & Melinda Gates Foundation in 2024, he held various leadership positions in the biotech companies Vir (VP Biomarkers) and Gilead Sciences, where he worked on the development and on market support of treatments for HCV (Sovaldi, Harvoni, Eplusa, and Vosevi). Additionally, he supported BARDA’s Project Next Gen, working to develop next generation therapies for the treatment of COVID-19. From 2019-2021 he worked at the Bill & Melinda Gates Foundation on the HIV Frontiers program, investing in novel technologies, research, and biomarker development focused on bringing curative therapies to resource limited parts of the world. Doehle obtained a B.S. in Biological Sciences and M.S. in Microbiology from Ohio University, a Ph.D. in Molecular Genetics and Microbiology from Duke University, and postdoctoral training at the University of Washington in innate immunology and viral sensing



## **CARLO SACDALAN**

Carlo Sacdalan is the head of the research physicians at the SEARCH Research Foundation (SEARCH) in Bangkok, Thailand. He is currently handling the acute HIV cohort (SEARCH010/RV254), the comparator study, SEARCH013/RV304, and the HIV remission trials associated with the acute HIV cohort. He is a published research physician with prior experience working for a clinical research organisation. Sacdalan earned his dual MD and MBA from the Ateneo School of Medicine and Public Health in Manila, Philippines, and his MSc in Public Health from the University of London, London School of Hygiene and Tropical Medicine



## **CARLOS DIAZGRANADOS**

Carlos Diazgranados is a Medical Doctor, native of Colombia, with postgraduate trainings in Internal Medicine and Infectious Diseases from University of Miami and Emory University, respectively. He also completed a Master of Science Programme in Clinical Research at the Emory University School of Arts and Sciences. After completing his postgraduate education, he practiced medicine and infectious diseases in his native country of Colombia for several years and was Assistance Professor of Medicine and Clinical Research at the FUCS University in Bogota. During that period, he led the development of the first national evidence-based guidelines for the prevention and management of HIV for the Country of Colombia, commissioned by the Colombian Ministry of Health. In 2006 he returned to Atlanta where he was faculty (Assistant Professor) with the Division of Infectious Diseases at Emory University. In 2009 he joined the Research and Development Division of Sanofi Pasteur, where he led multiple clinical vaccine development programmes (influenza, RSV, TB, HIV, Dengue, COVID). After a 12-year tenure at Sanofi, he joined the Bill & Melinda Gates Foundation, where he has had the role of Senior Programme Officer for HIV Vaccines and Biologics for the last 2.5 years



## **CAROLINE TIEMESSEN**

Caroline Tiemessen heads the Cell Biology Research Laboratory within the Centre for HIV and STIs at the National Institute for Communicable Diseases (NICD) and holds a joint appointment as Research Professor in Virology at the University of the Witwatersrand – where she also serves as the South African Department of Science and Innovation/ National Research Foundation (DSI/NRF) Chair of HIV Vaccine Translational Research. Her laboratory, which has expertise in virology, immunology and host genetics, focusses on the study of natural HIV resistance models. These include maternal-infant HIV-1 transmission for studying protective immunity to HIV-1, and the study of long term nonprogressors and elite controllers to understand natural attenuation of disease progression – to inform HIV vaccines and HIV cure. Another major focus of her research efforts is towards the goal of achieving paediatric remission/cure.



## **CATHERINE KOOFHETHILE**

Catherine Koofhethile is based at Botswana Harvard Health Partnership (BHP) as a Research Scientist where she works closely with Prof. Sikhulile Moyo and Dr Joe Makhema. She also holds an adjunct Professor Position at the University of Venda, SA. She completed her postdoctoral fellowship from Harvard T H Chan School of Public Health in the US where she was mentored by Prof. Roger Shapiro, Prof. Max Essex, and Prof. Phyllis Kanki. She now holds a Visiting Scientist position at HSPH. She is also a Visiting/collaborating research fellow at The Ragon Institute of MGH, MIT and Harvard in the USA under the mentorship of Prof. Mathias Lichtenfeld and Prof. Xu Yu. Koofhethile holds a PhD in Immunology from University of KwaZulu-Natal, South Africa under the supervision of Prof. Thumbi Ndung'u and mentorship of Prof. Zaza Ndhlovu and Dr Christina Thobakgale-Tshabala where she characterised HIV specific immune responses associated with natural control of HIV-1 in a cohort of adults. She holds a master's degree in Immunology from University of Birmingham, UK and a Bachelor of Science Degree with Honors in Medical Microbiology from the University of Surrey, Guildford, UK.

Her current research focusses on the assessment of the genetic composition of HIV proviral reservoir and factors that drive HIV to persist long term in several cohorts including adolescents from Botswana who are receiving long-term ART. She has previously studied HIV-1 persistence in a cohort of infants from Mozambique who received ART early in life. She also studied how another type of HIV (HIV-2) persists in a different adult cohort. All this work is important for advancing HIV cure research. She is currently leading BHP's efforts of setting up adolescent HIV cure research in Botswana and facilitating technology transfer. She is involved in building capacity at BHP by co-mentoring students as well as young researchers.

She has previously been supported through Fogarty, HBNU, Harvard CFAR, SANTHE Collaborative grants and Campbell Foundation. She recently received several awards to support her research and path to independence. These include the SANTHE Path to Independence, Botswana's Ministry of Communications, Knowledge and Technology and Johns Hopkins CFAR Africure awards.



## **CECILIA COSTINIUK**

Cecilia Costiniuk is an Associate Professor in the Department of Medicine, Division of Infectious Diseases and Chronic Viral Illness Service at the McGill University Health Centre, and a clinician-scientist at the Research Institute of the McGill University Health Centre in Montreal, Canada. Her research programme focuses on the interplay between pulmonary immune disturbances and HIV lung reservoirs in people with HIV. She also studies the immunomodulatory effects of cannabinoids on HIV-associated inflammation and comorbidities. During the COVID-19 pandemic, she led the Canadian Institutes for Health Research Canadian HIV Trials Network (CIHR CTN) 328 study on COVID-19 vaccine immunogenicity in people living with HIV (COVAXHIV), which prospectively followed nearly 400 people with HIV in Canada, with a focus on individuals frequently underrepresented in clinical research. Costiniuk co-leads the CTN Vaccines and Immunotherapy Core and is also a member of the Canadian HIV Cure Enterprise (CanCURE) 2.0, a research collaboratory focused on studying HIV persistence during antiretroviral therapy and developing strategies towards a sustainable HIV remission. At her institution, she has implemented a research autopsy protocol for PWH interested in donating tissues postmortem to advance HIV cure research. Costiniuk also works closely with members of the community advisory committees of both the CTN and CanCURE to design and conduct studies related to participant perspectives on HIV cure research. Costiniuk was a 2022 recipient of the Canadian Association for HIV Research – Canadian Foundation for AIDS Research (CAHR-CANFAR) Excellence in HIV Research Award in recognition of her track record of excellence and her demonstrated commitment to improving the lives of those living with, or at risk for, HIV.



## **CHARITY WAMBUI**

Charity Wambui is a physician and adjunct lecturer at The Moi University College of Health Sciences, department of Internal Medicine. She holds the positions of CRS leader for the Moi university Clinical Research Centre (MUCRC). She has a deep passion for offering quality care to the underserved. This passion extends to her desire to ensure equity in research for the African populace.



## **CHRISTY COMEAUX**

Christy Comeaux is an experienced physician-scientist in clinical development with 5+ years of industry experience. She has a MD-PhD from Harvard Medical School, with clinical experience in obstetrics & gynaecology and research experience in immunology & infectious diseases. Currently, she is a Senior Medical Director at BioNTech US, leading development on multiple infectious disease programmes. Comeaux previously held a director-level position for 4+ years as Medical Lead with Janssen Vaccines & Prevention (Johnson & Johnson) working on the global RSV vaccine clinical development programme. Comeaux is valued by colleagues as a natural, effective leader and a strong communicator. She has extensive experience presenting on behalf of her team to external and internal stakeholders (e.g., ACIP working group, internal Development Committee), at multiple conferences and to Health Authorities (e.g., FDA, EMA, CDE, PMDA). Comeaux is also experienced at providing oversight of trial physicians on Phase 1 FIH to global Phase 3 studies, key member of large cross-disciplinary teams with matrix structure, and programme lead of the product development team.


Comeaux previously worked in global health for a European funding agency supporting clinical trial research and capacity building in Sub-Saharan Africa in the role of Scientific Advisor for HIV and Maternal & Child Health projects.



## **CISSY KITYO MUTULUZA**

Cissy Kityo Mutuluza is a Public Health specialist and Epidemiologist with >30 years of experience in HIV/AIDS care, treatment and research. She is a pioneer of antiretroviral therapy (ART) use in sub-Saharan Africa from 1992 and has been at the forefront of scaling up care and treatment since 2003. She has overseen USAID/PEPFAR funded programmes to scale up HIV treatment and strengthen health systems for the delivery of care for the last 20 years. She has been PI/Co-PI or investigator for >80 research projects many of this pioneering research that has informed policy and clinical practice in Uganda and other developing countries. She is the Chief Investigator for the first trial of Long-Acting ART in Africa (8 sites, 3 countries) and working towards pioneer gene therapy research for HIV CURE in Africa. She co-founded the Global Gene Therapy Initiative (GGTI)

with over 60 experts to bridge the existing gaps and implement gene therapy research for eventual access in LMICs.




## **CLIVE MICHELO**

Clive Michelo's academic background is predominantly in molecular biology. He is very enthusiastic about human immunology basic science research and currently focused on characterising T cell responses to HIV-1 epitopes as a primer to vaccine design and development. However, he is also keen on learning societal perceptions, dynamics, and influences that are key in defining and perhaps guiding the basic science research agenda for effective translation of basic science. As such, some level of community engagement through effective communication is a skill he is hoping to develop along with his basic research experience. Ultimately, he hopes to build his capacity to devise original and innovative approaches for the generation of Africa centred biomedical interventions and provide some working framework for nurturing and mentoring more upcoming African scientists.



## **COLIN HAVENAR-DAUGHTON**

Colin Havenar-Daughton is a Senior Director of Immunology at Vir Biotechnology. He earned his PhD degree in Immunology from the University of Washington. He conducted postdoctoral studies in Shane Crotty's laboratory at the La Jolla Institute, where he focused on the immunological underpinnings of vaccination and applied these learnings to HIV vaccine development. At Vir, he contributed to the development of the SARS-CoV2 mAb (Sotrovimab) and is currently heading a research project on HIV functional cure.



## **CYNTHIA LUNGU**

Cynthia Lungu is an Early-stage Researcher at the Erasmus Medical Centre in the Netherlands. She also holds a research fellow position at the Centre for Infectious Disease Research in Zambia (CIDRZ). She obtained a BSc degree in Biological Sciences (Microbiology) from the University of Zambia and a MSc degree in Infection and Immunity from Erasmus University Rotterdam. She conducted doctoral research at Erasmus University Medical Centre, where she evaluated and applied technologies to study HIV reservoir dynamics in pre-clinical and clinical strategies towards HIV cure. Lungu recently received independent research funding for studies at CIDRZ in Lusaka, where she is leading efforts to establish an HIV persistence research programme in a low-resource, high disease burden setting to inform global scientific efforts on the development and implementation of novel HIV therapeutics.



## **DAMALIE NAKANJAKO**

Damalie Nakanjako is a Professor of Medicine and Principal of Makerere University College of Health Sciences, Fellow of the Uganda National Academy of Science and immediate past Dean of the School of Medicine. She holds a Bachelors' degree in Medicine and Surgery (MBChB) and Master of Medicine MMED in Internal Medicine from Makerere University, a PhD from the University of Antwerp, Belgium and a certificate in Leadership and Management in Health from the University of Washington, Seattle, USA. She has over 24 years' experience in Infectious Diseases care, research and training in resource-limited settings. She is the scientific director of the translational Laboratory at Makerere University's Infectious Diseases Institute, and she leads the Cluster of Excellence in translational research in Infection, immunity and inflammation; a collaborative network between the African Research Universities Alliance (ARUA) and GUILD of European Research-Intensive Universities.

Her research focuses studies to understand chronic HIV-associated inflammation and immune recovery during long-term HIV treatment, including the role of HIV viral reservoir characteristics in persistent immune activation and immune aging in HIV treatment cohorts in Africa. She is the Uganda PI and executive committee member of the "Research Enterprise to Advance a Cure for HIV" (REACH), one of the Martin Delaney HIV co-laboratories at Well Cornell Medicine, a multi-site and multi-national collaborations to search for an HIV cure.

Nakanjako is winner of the 4th Fourth Annual Merle A. Sande Health Leadership Award 2013 in recognition of her contributions towards leadership and health care in Africa, and the 2022 recipient of the World Academy of Sciences (TWAS) – Abdool Karim Award

in Biological Sciences; that was designed to honour women scientists in Low Income African Countries for their achievements in Biological Sciences. She has mentored over 58 upcoming scientists at masters', doctoral and post-doc levels, to build the next generation of scientists in Africa and worldwide.



## **DANIEL MUEMA**

Daniel Muema is a scientist at the KAVI Institute of Clinical Research in University of Nairobi, his work entails the characterisation of immune responses and pathogenesis of HIV. Muema is particularly interested in investigating the factors that are associated with the development of the best antibody responses that can be used to protect from HIV infection or eradicate established HIV reservoirs, such as neutralising antibodies. To achieve this, he is characterising HIV reservoirs in tissues and assessing if vaccine-induced antibodies can prevent viral rebound in the event of ART interruption. He also assesses if candidate HIV vaccines induce the desired antibodies.



## **DEBORAH PERSAUD**


Deborah Persaud is a Professor of paediatrics at the Johns Hopkins University School of Medicine, and the director of the Division of Paediatric Infectious Diseases at Johns Hopkins Children's Centre. She holds joint appointments in international health and molecular microbiology and immunology at the Johns Hopkins Bloomberg School of Public Health.

A clinician and researcher specialising in the study and treatment of HIV-1 infection in children, she directs the paediatric infectious diseases fellowship programme at the Johns Hopkins Children's Centre.

Persaud received her B.S. in chemistry from York College in New York. A 1985 graduate of the New York University School of Medicine, she trained in paediatrics at Babies Hospital/ Columbia Presbyterian Medical Centre in New York, where she was chief resident. She was an infectious disease fellow, an Aaron Diamond postdoctoral research fellow and a faculty member at New York University. She joined the Johns Hopkins faculty in 1997, following a visiting lectureship at the Moi University in Eldoret, Kenya.

Her research interests include HIV/AIDS drug development and mother-to-child HIV transmission.

Persaud is the scientific chair of the HIV CURE Scientific Committee of the International Maternal, Paediatric Adolescent AIDS Clinical Trials (IMPAACT) group. She was awarded the prestigious Elizabeth Glaser Scientist Award for her HIV research and was recognised by Nature magazine in 2013 as one of "Ten People Who Mattered This Year." She was recognised by Time magazine as among the "100 Most Influential People of 2013" for her paediatric HIV treatment research.



## **DEVI SENGUPTA**

Devi SenGupta is Executive Director of Clinical Development at Gilead Sciences, leading the company's HIV cure development programme. Prior to joining Gilead in 2015, she was a physician scientist and Assistant Professor at the University of California San Francisco (UCSF). Her NIH-funded programme focused on translational HIV immunology research. SenGupta received her Bachelor of Arts degree in Psychology/Biology at Harvard University, M. Phil. in Neuropsychology at Cambridge University (U.K.), M.D. at the University of Washington School of Medicine, and completed her internal medicine residency at Johns Hopkins Hospital and infectious diseases fellowship at UCSF. During her time at Gilead, she has led HIV treatment, cure as well as COVID-19 clinical trials and programmes and is a member of the HIV Franchise Strategy team. As global development and strategy lead of the HIV cure programme, SenGupta provides direction for cross-functional internal teams and external multi-stakeholder collaborations developing combination approaches aimed at achieving long-term HIV remission. She is also the newly named global Chair of the Women at Gilead Employee Resource Group. SenGupta's external leadership roles include the International AIDS Society (IAS) HIV Cure Industry Collaborative Group and the Advisory Council of the California HIV/AIDS Research Program (CHRP).



## **DOMINIC KEMPS**

Dominic is the Director of Programmes at the HIV Cure Africa Acceleration Partnership (HCAAP), a global platform co-chaired by Mark Dybul, Georgetown University and Izukanji Sikazwe CIDRZ that was established to improve collaboration, define clear targets and engage communities in the HIV cure research and development cycles through to improving access, community literacy and demand generation for innovation in HIV treatments to cure. Dominic brings over 20 years' experience building collaboration between communities, health systems, donors (of all kinds) and government, including 15 years within the life sciences sector, as the Global Technical Lead for CLM at UNAIDS to being the Global Head of Positive Action at ViiV Healthcare before this; and earlier within the Corporate Responsibility team at Pfizer and at Interact Worldwide a global SRHR NGO.




## **DONN COLBY**

Donn Colby is a Research Physician at the U.S. Military HIV Research Program (MHRP). Based in Seattle, WA, he supervises collaborative studies with Joint Base Lewis-McChord (JBLM) in Washington State and contributes to clinical protocols implemented in Asia. Prior to joining MHRP in 2019, he was a co-investigator on the RV254 trial of acute HIV infection and the project lead on a number of clinical trials implemented in collaboration with MHRP at the Thai Red Cross AIDS Research Centre in Bangkok, Thailand.

Colby received his B.A. in Biology at Johns Hopkins University and his M.D. at the State University of New York at Stony Brook. He did his internal medicine residency training and Masters in Public Health at the University of Washington in Seattle. In 2001 he received a Fulbright Scholarship to study the epidemiology of HIV in Vietnam, leading to over two decades of collaborative work in Southeast Asia. He was voted Distinguished Alumni of the year by the University of Washington School of Public Health in 2006.

Colby has published extensively on the epidemiology of HIV in Southeast Asia, clinical outcomes among people living with HIV, the implementation of preexposure prophylaxis (PrEP), and clinical trials of novel therapeutics investigating the potential to cure HIV infection. He is also an academic editor for PLoS One and has participated as an ad hoc reviewer on multiple NIH review panels screening grant proposals for HIV clinical and preventive studies.



## **ELENA VENDRAME**

Elena Vendrame is a Director of Clinical Development at Gilead Sciences, Inc, in the virology therapeutic area. Vendrame completed an Infectious Diseases fellowship at Stanford University in 2018. From 2018 to 2020 she was an Instructor in the Department of Medicine, Division of Infectious Diseases and Geographic Medicine, where her work focused on HIV immunopathogenesis and profiling of the NK cell repertoire and function in people living with HIV.

She joined Gilead Sciences in 2020, where she oversees the clinical development of biologics for HIV cure, and leads multiple HIV cure clinical trials. She also continues to serve as a Clinical Adjunct Assistant Professor at Stanford University, in the Department of Medicine, Division of Infectious Diseases and Geographic Medicine, where she works as an HIV specialist.



## **ELIZABETH BARR**

Elizabeth Barr is the Associate Director for Interdisciplinary Research at the NIH Office of Research on Women's Health (ORWH). Barr joined ORWH in 2019, where she has coordinated ORWH's efforts to advance intersectional health research on gender as a social and structural variable, managed the ORWH interprofessional education programme, and led efforts to advance HIV research for women. Barr's background is in gender & women's studies, community-led HIV research and reproductive justice. She completed her Ph.D. at the University of Wisconsin–Madison in Rhetoric, Politics, and Culture and her M.S. Towson University in Women's and Gender Studies. Prior to joining ORWH, Barr served on the faculties of Towson University and the University of Maryland, Baltimore County and led interdisciplinary, cross-sector projects to increase women's engagement in clinical research.



## **ELLIOT RAIZES**

Elliot Raizes has been working to support CDC’s global response to the HIV pandemic as a member of HIV Care and Treatment Branch since 2007 including as the Adult Treatment Team Lead from 2016-2022 and as branch chief since August 2022. He has been providing technical assistance to Ministries of Health, CDC staff and implementing partners in PEPFAR-supported countries over the past 16 years. He has also contributed to the development of global guidance on antiretroviral therapy and HIV drug resistance through his role on multiple WHO guideline groups and as a member of the WHO HIVResNet steering committee. Raizes presently serves as a member of the organising committee for the International HIV Drug Resistance Workshop and was the co-chair of the IAS forum on the Risks of Pre-conception Dolutegravir Exposure in 2018-19. He has served as co-lead of several initiatives at PEPFAR including the HIV drug resistance workgroup, the Epidemic Control Teams, and the PEPFAR COVID-19 response short term task team. He is a co-investigator on multiple country-based HIV drug resistance surveillance projects and has been a co-author on over 20 publications related to HIV drug resistance and antiretroviral therapy in resource-limited settings. Raizes also is a recipient of the PEPFAR Lifetime Achievement award.

Prior to joining CDC, he spent 20 years as consultant in infectious diseases, with emphasis on HIV management, in Gwinnett, Hall and Clarke counties in Georgia. Raizes, along with his wife Beth and others, co-founded Positive Impact Health Centers where he continues to care for patients on a weekly basis. He graduated from Northwestern University Medical School and completed his postgraduate training in internal medicine at Emory University and infectious diseases at the Medical University of South Carolina.



## **EMMANUEL SHANA**

Emmanuel Shana is a practising general medical practitioner from Zimbabwe’s second largest city of Bulawayo. A serving Board Member of the Medical Research Council of Zimbabwe (MRCZ) and is currently chairperson of the National Health Research and Development Committee (the ethics committee) at the MRCZ.



## **EUNICE NDUATI**

Eunice Nduati is a Research Scientist at the Kenya Medical Research Institute - Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya and a Principal Investigator with the International AIDS Vaccine Initiative (IAVI) - ADVANCE programme. She is also a member of SANTHE’s Consortium Steering Committee. Her research interests are in understanding host immune responses to infectious pathogens common in sub-Saharan Africa to inform vaccine development. Her work focuses on HIV, to understand cellular and molecular mechanisms involved in the generation of HIV-specific antibodies with relevant functions that may inform vaccine development. In addition, she is interested in assessing population immune baselines and how these impact vaccine outcomes across populations. As part of a collaborative programme with IAVI, Nduati has established immunogenicity testing frameworks for HIV vaccine studies. Understanding contemporaneous viral evolution and its impact on current HIV immunogen design is also an emerging interest within her group. Nduati also has a keen interest in scientific and technical capacity building in Africa.



## **FREDRICK SAWE**

Fredrick Sawe is the Director (HJFMRI) of the Kenya Medical Research Institute, United States Army Medical Research Directorate-Africa Kenya Programme in Kericho, Kenya which is part of the U.S. Military HIV Research Program’s international research network. Sawe leads all research and HIV prevention, care, treatment and research activities for this site and the South Rift Valley Region respectively. Sawe is a Specialist Obstetrician and Gynaecologist who has worked in the Kericho area for more than 30 years.

Sawe has played a key role in the execution of several HIV vaccine and therapeutic clinical trials and related HIV cohort studies in Kericho among other studies. Sawe is the Clinical Research Site (CRS) leader for Kericho for the National Institutes of Health (NIH) funded networks of HIV research and has been a Chair or Principal Investigator on a number the protocols being implemented at the site, including studies sponsored by the US Army and the US National Institutes of Health, including; AIDS Clinical Trial Group



(ACTG), International Maternal, Paediatric, Adolescent, AIDS Clinical Trials (IMPAACT), HIV Vaccine Trials Network (HVTN) and Corona Vaccine and Prevention Network (COVPN) studies.

Since 2004, Sawe has been in charge of MHRP's South Rift Valley Province (SRV) President's Emergency Plan For AIDS Relief (PEPFAR) activities.

Sawe graduated from medical school at the University of Nairobi, Kenya. He also received specialised training for health care in developing countries and AIDS care and prevention from the Boston University School of Public Health and Makerere University in Kampala, Uganda.



## **GABRIELA CROMHOUT**

Gabriela Cromhout is a medical doctor from South Africa, who is currently working in Paediatric Human Immunodeficiency Virus (HIV) Research in KwaZulu- Natal, South Africa - with a particular focus on and interest in HIV cure and TB-HIV treatment research. Cromhout is the Clinical Co-ordinator of the Ucwningo Lwabantwana ('Baby Cure') Study and also works as one of the Study Clinicians on the study, as well as the Study Clinician on the UKZN-CAPRISA ORCHID Study. She is currently a PhD candidate at the University of KwaZulu-Natal and completed her MSc in Tropical Medicine and International Health and DTM&H at the London School of Hygiene and Tropical Medicine in 2020. Cromhout's work and studies focus on her pursuit to further research and knowledge towards an HIV cure.



## **GARETH TUDOR-WILLIAMS**

Gareth Tudor-Williams is an Emeritus Professor of Paediatric Infectious Diseases at Imperial College London, having retired as a Consultant in PID at Imperial College Healthcare NHS Trust, St. Mary's Hospital, London in September 2021.

After working in Nepal for Save the Children Fund UK, 1982-84, he later specialised in HIV infection in children, training for 5 years in the USA at Duke University and the NIH, Bethesda, MD. From 1994-2021 he was a member of the PID group at Imperial College London, involved in international Phase II and III trials relating to paediatric blood-borne virus infections. In collaboration with Prof. Philip Goulder, he has been involved in ATI trials in young HIV-infected children since 2001.

Tudor-Williams was the founding Chair of CHIVA (Children's HIV Association of the UK and Ireland). In semi-retirement, he is chair of the Penta Network Engagement Committee, and is a Visiting Professorship at Chulalongkorn University, Bangkok, Thailand. He also chairs the London Central Research Ethics Committee for the Health Research Authority UK.



## **GBOLAHAN AJIBOLA**

Gbolahan Ajibola is a trained physician with a master's in public health and over 10 years' experience in clinical research at Botswana Harvard Health Partnership (BHP). His research focuses on maternal-child health.

Current projects and role:

- Early Infant Treatment Study (Co-Investigator)
- Point-of-Care HIV Testing and Early Dolutegravir Use for Infants (Principal Investigator)
- A Clinical Trial to Evaluate the Impact of Broadly Neutralising Antibodies (bNAbs) VRC01LS and 10- 1074 on Maintenance of HIV Viral Suppression in a Cohort of Early-Treated Children in Botswana". (Co-Investigator)
- Phase I/II Trial to Evaluate the Impact of Three Broadly Neutralising Antibodies or Analytic Treatment Interruption on Viral Reservoir, Immune Function, and Maintenance of HIV Suppression in Early-Treated Children in Botswana (Protocol Vice-Chair)



## **GODELIEVE DE BREE**

Godelieve de Bree serves as an internist-infectiologist and clinical immunologist at the Academic Medical Centre (AMC) since 2015. Her focus lies in pioneering translational HIV research, particularly emphasising acute HIV infection and the development of HIV cure treatment strategies. Concurrently, de Bree is deeply engaged in the study of primary and secondary immunodeficiency diseases, fostering a comprehensive understanding of these clinical conditions through both national and international collaborations.

Her groundbreaking research in acute HIV infection and HIV cure strategies is delineated into three key areas:


- **City-Oriented HIV Epidemic Strategy:** As the scientific coordinator of the HIV Transmission Elimination Amsterdam (H-TEAM) initiative, de Bree spearheads innovative approaches to combat the HIV epidemic at a city level. Through this consortium, she leads various projects focused on transmission networks, particularly among populations with migration backgrounds, and endeavours to improve outreach to individuals entering care late.
- **Acute HIV Studies and NOVA Cohort:** de Bree has been at the forefront of acute HIV studies at the AMC since 2013, having initiated the Netherlands Cohort Study on Acute HIV Infection (NOVA study). This national cohort study investigates the effects of early treatment initiation on immunity and viral reservoirs. Additionally, she leads a grant-funded project in collaboration with UMCU and Erasmus Medical Centre, aimed at identifying new treatment strategies for HIV cure.
- **Clinical Trial on HIV Vaccine Efficacy:** de Bree and her team have developed a pioneering clinical trial to evaluate the efficacy of an HIV vaccine, scheduled to commence in October this year. This collaborative effort aims to advance preventive measures against HIV infection.

As a clinical scientist with expertise in immunology, de Bree bridges the gap between pre-clinical research and clinical trials, driving forward the investigation of innovative avenues in HIV treatment and prevention.



## **HANNAH KIBUUKA**

Hannah Kibuuka is an executive director at the Makerere University Walter Reed Project (MUWRP). She is a research scientist and clinician with over 15 years of HIV and Ebola Research experience. She is actively engaged in clinical trials to test vaccines for HIV, Ebola/Marburg, COVID-19, and Schistosomiasis and in surveillance for emerging and re-emerging infections and Antimicrobial resistance. She provides strategic direction, leadership and administrative oversight of Makerere University Walter Reed Project. For the last 3 years, she has been working with the HOPE Collaboratory on cure research using the Block-Lock-Excise (Stop) approach that entails the long-term durable silencing of viral expression of latent virus and control of virus infection in absence of therapy.



## **HARRIET MAYANJA-KIZZA**

Harriet Mayanja-Kizza is an internist, trainer and researcher at Makerere University College of Health Sciences, with a Masters of Medicine, Masters of immunology, and a Doctorate in Biomedical Sciences.

Mayanja-Kizza is a Professor of Medicine at Makerere University, former Chair Department of Medicine, and former Dean of the School of Medicine, Makerere University in addition to serving on the Makerere University Senate and Council.

As a trainer at Makerere School of Medicine, she teaches undergraduates, postgraduates and supervise Masters and Doctoral research. She also mentors' students at different levels as well as junior physicians especially those active in research. Mayanja-Kizza is also the Co- Director of the Makerere-Yale global health programme, now in its 18th year, and an adjunct lecturer at Case Western Reserve University.

Over the last 20 years, she has been conducting research in the area of tuberculosis, and HIV, with emphasis on tuberculosis/HIV co-interaction and immuno-pathogenesis, tuberculosis disease biomarkers, and clinical trials. Mayanja-Kizza has been an investigator on various clinical and immunological studies within the Uganda CWRU Research Collaboration, and is currently a site co-principal investigator, and a study PI on the specific clinical studies and biomedical studies in tuberculosis and related infections.

She has been a member of various LMIC research groups, including the NACCAP with Rwanda and Netherlands, CEBHA, with Ethiopia, Rwanda, Malawi, South Africa and Germany, TB biomarker studies with the Gambia, Namibia, South Africa, Germany, and currently on the SANTHE programme.

Mayanja-Kizza has mentored and supervised many students and researchers at Makerere University, as well as in other African countries including Ethiopia, Rwanda, Namibia, and South Africa, in addition to serving as an external examiner at universities in Uganda, Kenya, Rwanda, Tanzania and South Africa.

She serves as a reviewer of varied journals including BMC (ID) –where she is a co-editor,

Plos One, Lancet ID, the Uganda based African Journal of health Sciences and other varied journals.



## **JEFFREY LAURENCE**

Jeffrey Laurence is a Professor of Medicine in the Division of Haematology and Medical Oncology at Weill Cornell Medical College and Attending Physician at New York Presbyterian Hospital as well as Senior Scientist for programmes at amfAR, The Foundation for AIDS Research. He is also Editor-in-Chief of Translational Research and AIDS Patient Care and STDs. He received his B.A. summa cum laude from Columbia University in 1972, and his M.D. with honours from the University of Chicago Pritzker School of Medicine in 1976. He was elected a Rhodes Scholar to Oxford University in 1973 and was a Henry Luce Scholar at the Institute for Cancer Research in Osaka, Japan from 1974-1975. His current research focuses on cardiac and renal side-effects of antiretroviral drugs as well as clotting disorders associated with endothelial cell injury and complement activation in HIV, COVID-19 and other conditions.



## **JESSICA SALZWEDEL**

Jessica Salzwedel is a Senior Programme Manager of Research Engagement at AVAC, a non-governmental organisation based in New York City. Salzwedel leads the HIV cure research advocacy work- developing research literacy materials, policy analysis, and developing global networks of advocates contributing to the acceleration of HIV cure research.

She also serves as the community engagement coordinator for Research Enterprise to Advance a Cure for HIV, Immunotherapy for Cure, and Paediatric Adolescent Virus Elimination (REACH, I4C and PAVE respectively), three of ten NIH-funded international collaboratories aimed at developing therapeutic interventions to cure HIV infection. Salzwedel is an expert on Good Participatory Practice, a framework for integrating stakeholders throughout the research lifecycle. Over the past ten years she has developed a suite of online and in-person trainings to translate the GPP guidelines into action and has supported research sites, sponsors and advocacy organisations develop stakeholder engagement programmes.

Before working at AVAC, she was part of the Bioethics team at the Division of AIDS at the National Institute for Allergy and Infectious Diseases.

Salzwedel earned a Master's degree from New York University in Bioethics and holds an undergraduate degree in Biology from Union College



## **JILLIAN LAU**

Jillian Lau is a postdoctoral research fellow in the Lewin Laboratory at the Doherty Institute and an Infectious Diseases Physician at the Royal Melbourne Hospital and Alfred Hospital in Melbourne, Australia. Her research focuses on studying strategies to cure HIV, including immunotherapy and latency reversal agents. Her PhD studied analytical treatment interruptions (temporary pauses in HIV treatment in the context of a clinical trial) and her postdoctoral research explores factors associated with viral control off treatment. She is passionate about meaningfully engaging of people with HIV in Cure focused research.



## **JOHN DANVIC ROSADIÑO**

John Danvic Rosadiño is the Head of Programmes and Innovations of LoveYourself, a community-based organisation providing sexual health, transgender health, and mental health services for various communities in the Philippines. He has also initiated various community-based demonstration projects, feasibility studies, and implementation science research on HIV testing and prevention, Hepatitis C testing, and COVID-19 testing in the Philippines.



## **JOHN FRATER**

John Frater is a Professor of Infectious Diseases at the University of Oxford, where he leads the HIV Reservoir and Cure Group. The aim of his research is to explore strategies for targeting the reservoir of latent HIV infection in treated individuals, with a specific interest in primary HIV infection. He is a lead investigator on a number of major HIV

clinical studies (e.g. RIO, AbVax, RIVER, HEATHER), many of which include antiretroviral therapy treatment interruptions. His laboratory focus is on immune responses that may lead to viral control and the impact of viral variation. He also works as an Honorary Consultant Physician in the NHS in HIV and Infectious Diseases.



## **JOSEPH MAKHEMA**

Joseph Makhema is an Internal Medicine Physician by training and is the CEO of the Botswana Harvard Health Partnership (BHP). He oversees and has led BHP in conducting high-impact infectious disease research that has informed numerous WHO, UNAIDS, and US/European guidelines. These include numerous intervention clinical trials, community and capacity building initiatives funded by US Government, pharmaceutical industry, philanthropic foundations and other independent investigator sponsor awards. He is CO-PI of the Clinical Trials Unit trials affiliated to the ACTG, IMPAACT, COVPN and HPTN. He participates in quality management systems, monitoring and evaluation of studies conducted at the BHP. He has published and been involved in over 100 scientific publications. He is particularly interested in community HIV prevention initiatives, translational policy issues, and health systems strengthening.



## **JULIEN NYOMBAYIRE**


Julien Nyombayire is a research clinician at the Center for Family Health Research (CFHR), a long-standing clinical research institution established in Rwanda since 1986 and formerly known as Project San Francisco. With more than 10 years' experience in clinical research, Nyombayire has served as an investigator in several observational cohort studies as well as multicentre clinical trials of preventive vaccine and therapeutics in different infectious diseases area including HIV, Ebola, Covid-19 and Malaria. He has recently served as the Principal Investigator for the first ever Phase 1 clinical trial of an mRNA HIV vaccine candidate conducted in Africa and a co-investigator of the first large Phase 3 Ebola vaccine trial among pregnant women in Rwanda. In addition, Nyombayire has extensive experience in the management of large infection diseases prevention programmes (e.g. HIV, Ebola) involving most at-risk populations and in collaboration with large external funding agencies. In addition to safety follow-up of participants enrolled in clinical trials, Nyombayire is involved in the care and treatment of patients living with HIV and patients with symptoms of sexually transmitted infections (STIs) as part of his daily clinical duties.

Nyombayire currently serves as the Executive Director of CFHR. He holds a degree of General Medicine and Surgery from the National University of Rwanda and a Master's of Sciences degree in Clinical Trials from the London School of Hygiene and Tropical Medicine as well as several professional certifications in the management of clinical trials.



## **KARIN DUBÉ**

Karin Dubé is an Associate Professor at the University of California San Diego School of Medicine, Division of Infectious Diseases and Global Public Health. She is a senior socio-behavioural scientist and experienced research programme manager who integrates biomedical research, socio-behavioural sciences, ethics and patient engagement around HIV-related research in the United States and sub-Saharan Africa. She has 20 years of experience in infectious disease-related work.



## **KARL SALZWEDEL**

Karl Salzweidel is Chief of the Pathogenesis and Basic Research Branch of the NIAID Division of AIDS. He oversees a broad portfolio of grant funding, including the Martin Delaney Collaboratories for HIV Cure Research (MDC) program, the Centers for AIDS Research (CFAR) programme, the Centers for HIV Structural Biology, and the NIH HIV Reagent Program. Prior to joining NIAID, Salzweidel was Senior Director of Virology and Drug Discovery at Panacos Pharmaceuticals, Inc., where he led efforts to develop the first-in-class HIV maturation inhibitor, bevirimat, and identify orally bioavailable HIV fusion inhibitors. Salzweidel received his postdoctoral training at NIAID in the Laboratory of Viral Diseases studying the mechanism of HIV entry into cells. He earned his PhD in Microbiology from the University of Alabama at Birmingham and his BS in Biology from the University of North Carolina at Chapel Hill.



## **KATHARINE BAR**


Katharine Bar is an Associate Professor in the Department of Medicine at the University of Pennsylvania and directs the Virus and Reservoirs Core of the Penn Center for AIDS Research. At Penn, she is an infectious diseases provider and a translational physician-scientist studying novel approaches to HIV prevention and cure. Through her roles in the HIV Vaccines Trials Network and the AIDS Clinical Trials Group, Bar leads trials testing novel applications of antibodies for prevention, therapy and cure, and serves as the vice chair of the ACTG Cure Transformative Science Group.



## **KATHRYN STEPHENSON**

Kathryn Stephenson is a physician-scientist in the Center for Virology and Vaccine Research (CVVR) and the Division of Infectious Diseases at Beth Israel Deaconess Medical Center (BIDMC) in Boston, Massachusetts. She is also an Associate Professor of Medicine at Harvard Medical School. She has expertise in conducting phase 1 clinical trials testing novel immunologic interventions for HIV and emerging infectious diseases like SARS-CoV-2 and Zika virus. During the COVID-19 pandemic, she was the site Principal Investigator for the first-in-human trial of the Johnson & Johnson/Janssen Ad26.COVID-19 vaccine, as well as for the Phase 3 efficacy trials of remdesivir, Novavax vaccine, and casirivimab and imdevimab monoclonal antibodies. She is currently the protocol co-chair of CoVPN 3006, the largest federally funded study to test whether the Moderna COVID-19 vaccine can block SARS-CoV-2 transmission. This COVID-19 work complements her previous contributions in testing a mosaic Ad26-based HIV vaccine and broadly neutralising antibodies for HIV prevention, treatment and remission. In addition, Stephenson is an outspoken advocate for increasing research equity for Black and Latinx populations in clinical trials, and is committed to ensuring access to promising medicines and vaccines for our most vulnerable communities.

Stephenson received her medical degree from New York University, and completed her internal medicine training at Columbia NY Presbyterian Hospital, followed by infectious diseases training at Mass General Brigham. She also obtained a Masters in Public Health from Columbia University where she focused on the ethics of clinical trials, isolation and quarantine.



## **KRISTA DONG**

Krista Dong is an infectious disease physician and implementation scientist with expertise in design of robust, patient centred HIV-cure and prevention research protocols. Dong is an Assistant Professor of Medicine at Harvard Medical School and a core member of the Ragon Institute of MGH, MIT and Harvard. She has been living and working in sub-Saharan Africa since 1995, and in South Africa since 2000, where she is a passionate advocate for equitable enrolment in HIV cure research and trials globally.

In 2012, she established the Females Rising through Education, Support and Health (FRESH) Acute HIV cohort in Durban South Africa, enrolling adolescent girls and young women at extraordinarily high-risk of HIV acquisition and performing frequent HIV-RNA monitoring to detect acute HIV-infection at the earliest timepoints to enable study of the first immunological responses and viral dynamics.

Unique to the design of FRESH is that all study participants are co-enrolled in an empowerment and poverty-alleviation programme with classes that coincide with the frequent study visits. The FRESH site team works closely with investigators, participants and the community to ensure each step of the iterative research design process keeps participants at the core of the effort, to inform current and future protocols and interventions.

Under Dong's leadership, FRESH has expanded to become an active clinical trial site optimised for early-phase studies to test novel interventions for HIV prevention and cure. One focus area at FRESH is to advance treatment options for vaginal dysbiosis, having shown that the associated inflammation is associated with a 3-fold increase HIV acquisition risk. FRESH just completed a novel HIV prevention study, Phase 2 placebo-controlled randomised trial of LACTIN-V (Lactobacillus crispatus CTV-05) among women at high risk of HIV acquisition in Durban, South Africa, and is currently conducting a first-in-Africa HIV cure trial, A Phase 2a Study to Evaluate the Safety and Tolerability of a Regimen of Dual Anti-HIV Envelope Antibodies, VRC07-523LS and CAP256V2LS, in a Sequential Regimen with a TLR7 Agonist, Vesatolimod, in Early Antiretroviral-Treated HIV-1 Clade C-Infected Women.



## **LEBOHANG MOLIFE**

Lebohang Molife serves as the Medical Director, Clinical Development at the International AIDS Vaccine Initiative (IAVI), overseeing the design and execution of HIV vaccine trials and observational studies. With a background in medical affairs within the pharmaceutical and medical device sectors, she has spearheaded integrated evidence generation initiatives. Her expertise also extends to clinical trial project management, with a focus on HIV prevention studies. Additionally, Molife has contributed to health systems strengthening projects, particularly in collaboration with key populations.



## **LINDA MURUNGI**

Linda Murungi is a strategic, transformative leader who has managed research initiatives spanning many local and globally recognised centres. As the go-to leader and subject matter expert in the technical implementation of scientific research programmes, she has more than 12 years of regional leadership experience working in international research and not-for-profit organisations. This includes conceptualising and developing research proposals, creating protocols and technical manuals, critical and objective analysis of complex scientific data, and creating technical reports for funders and collaborators.

Murungi is praised for her capacity to train, guide, and support upcoming research leaders in Africa while also creating, introducing, and directing the acceptance of standards and best practices. She is unmatched in her ability to seek continuous improvements in team performance, deliverables, and scientific excellence in the field of vaccines, including novel technologies and platforms. Her leadership of end-to-end high-level technical oversight for dynamic, goal-oriented research activities has also been crucial to guaranteeing high-quality results.

Murungi possesses exceptional abilities in the areas of strategic direction, vaccine development through implementation, and knowledge of pre-clinical and clinical development and translational science. She is a strategic thinker who has the capacity to grasp the big picture while keeping cognisant of the real-world effects of choices made.



## **LINGHUA LI**

Linghua Li has served as a physician specialising in HIV infection and AIDS, as well as other infectious diseases such as fungal infections and oncology, at Guangzhou Eighth People's Hospital affiliated with Guangzhou Medical University, since 1997. Currently, she holds the position of Head Director at our hospital's Infectious Disease Centre where her expertise lies within Clinical Medicine and Internal Medicine. Additionally, Li is implementing clinical trials at their outpatient department for patients living with HIV and key populations at risk of acquiring HIV falls under her responsibility. Until now, she has been sponsored in more than 20 programmes, both domestic and overseas. Li play the role of PI in some representative grants, such as the National Natural Science Foundation of China (grant number: 81301480) aiming to investigate the mechanism and function of Phospholipase B on the growth and pathogenicity of *P. marneffei*, Guangdong Natural Science Foundation (grant number: 10151006002000000) aiming to investigate the role and mechanism of Phospholipase B when *P. marneffei* invades the macrophage of AIDS patients and NIH Fogarty aiming to investigate the role of host factors in this serious opportunistic complication of AIDS will provide insights into its pathogenesis and pave the way for potential targeted prophylactic strategies. 2 years ago, she started to do researches in HIV PrEP studies in Guangzhou being the Co-PI of a Phase IV clinical trial that aimed to promote PrEP among key populations in China (ChiCTR2100048981 and NCT04754139). The trial, the largest of its kind in China, aims to provide PrEP to 1,200 eligible men. Until 2023, they successfully enrolled 1,007 participants, 950 of whom were already on PrEP.



## **LOUISE KUHN**

Louise Kuhn is a faculty member in the Gertrude H. Sergievsky Centre and in the Department of Epidemiology at the Columbia University Irving Medical Center. She manages an international research programme on HIV/AIDS among women and children. She has a Ph.D. from Columbia University, New York; and M.A. from the University of Cape Town, South Africa. She teaches courses and mentors graduate students in the Epidemiology programme of the Mailman School of Public Health.



## **LUIS J. MONTANER**

Luis J. Montaner is Vice President for Scientific Operations and Herbert Kean, MD, Family Professor at The Wistar Institute. He is programme leader for HIV Research and leads the cure-directed BEAT-HIV Martin Delaney Collaboratory program. Montaner has completed several clinical studies in person living with HIV including undergoing treatment interruption in Philadelphia and South Africa as well as sponsored educational videos and a position paper on the role of treatment interruption in cure-directed studies (see [beat-hiv.org](http://beat-hiv.org)). Montaner serves on the board of Philadelphia FIGHT, the city's largest FQHC serving people living with HIV. Montaner's research programme centres on innate immune responses, immune reconstitution in opioid use disorder/HIV-1 infection, and macrophage biology in cancer microenvironments. As leader of US and international academic-industry partnerships including basic and clinical trial efforts, the lab explores ways to boost natural function of the immune system to combat infection or cancer. Montaner served as editor-in-chief of the *Journal of Leukocyte Biology* from 2009-2023. He is also a member of the Penn CFAR, Office of AIDS Research Advisory Committee, and is originally from Puerto Rico.



## **LYDIE TRAUTMANN**

Lydie Trautmann is the Director of Translational Research, Global Infectious Diseases Portfolio, at the Henry M Jackson Foundation in support of the U.S. Military HIV Research Program, MHRP. She oversees the research efforts in the current and upcoming MHRP HIV remission clinical trials. She also co-leads the International NeuroHIV Cure Consortium. Trautmann received her Engineer Doctor degree in 1998, and her Ph.D. in Immunology at Paris V University in 2003. Prior to her role at HJF/MHRP, she performed research for two decades in translational human immunology at the Vaccine and Gene Therapy Institute in Florida, MHRP and the Oregon Health and Science University.



## **MAHOMED YUNUS MOOSA**

Mahomed Yunus Moosa is an Associate Professor, Chief Specialist and Head of the Department of Infectious Diseases at the University of KwaZulu-Natal. His work focuses on the care of inpatients and outpatients with complex infectious disease issues. He is involved in teaching and training medical students, postgraduates at all levels, and Infectious Diseases Subspecialists. His is widely published in his research interests which include HIV drug resistance, diagnosis of smear negative tuberculosis and TB drug induced liver injury. He is the recent past President and Chair of the Board of Directors of the Southern African HIV Clinicians Society (SAHCS).



## **MARCEL TONGO PASSO**

Marcel Tongo Passo returned to his home country, Cameroon, in 2018 after his post-graduate training in South Africa. He sought to establish an independent research career, build his own laboratory, and recruit PhD Fellows. His major interest lies in understanding the mechanisms of strain selection during HIV emergence. The extraordinary diversity of HIV-1 group M poses the most important obstacle to the development of both a cure and an effective vaccine. The Congo Basin area is the epicenter of HIV-1 emergence and has the broadest HIV diversity with numerous recombinant forms and unique strains. It is therefore particularly important to fully understand the biological underpinnings of this diversity: both how it arose, spreads, and impacts the extent and duration of individual sub-epidemics. A successful vaccine and cure strategy has to deal with the issues of HIV emergence and understand the factors governing emergence, as the vaccine formulas should cover all the emergent strains in order for the strategy to be effective.

Tongo Passo also has some interest in monitoring the occurrence of past and current viral zoonoses in the Congo Basin region which has one of the highest human-animals interaction; as the global crisis precipitated by the SARS-CoV-2 pandemic clearly illustrates the consequences of a single viral zoonotic transmission into human populations.



## MARIA PAPATHANASOPOULOS

Maria Papathanasopoulos directs the HIV Pathogenesis Research Laboratory in the Department of Molecular Medicine and Haematology at Wits where she also lectures. An established scientist who has built an exceptional reputation in the infectious diseases, bioinformatics, and virology fields. She has established world class laboratories that conduct innovative research on HIV-1 drug discovery and vaccine designs that are recognised at a national, regional and international level. In the last eight years, she has completed research for the South African Strategic Health Innovation Platform, the South African HIV/AIDS Research and Innovation Platform, the National Research Foundation, the International AIDS Vaccine Initiative Innovation Fund, the Carnegie Foundation, the Poliomyelitis Research Foundation and several others.



## MARINA CASKEY

Marina Caskey is a Professor of Clinical Investigation at The Rockefeller University. Her work focuses on the development and clinical evaluation of novel immunotherapeutic strategies against infectious diseases, with a special emphasis on HIV. Caskey has led a series of early-phase clinical studies to evaluate the safety and efficacy of broadly neutralising anti-HIV antibodies. These studies have revitalised this area of HIV research, which had been abandoned after first-generation antibodies failed to show significant effects in humans. Broadly neutralising antibodies are now considered one of the most promising strategies to achieve HIV remission, as well as potential alternatives to antiretrovirals for both therapy and prevention.

Caskey graduated from medical school at the Federal University of Sergipe in Brazil. She then completed an internal medicine residency at Saint Luke's Roosevelt Hospital, in New York, followed by fellowship training in infectious diseases at New York Presbyterian-Weill Cornell Medical Center. She currently serves as the Chair of the Cure Transformative Science Group of the ACTG. Caskey is also an attending physician in infectious diseases at Weill Cornell Medicine Center and an elected member of the American Society of Clinical Investigation.




## MARK COTTON

Mark Cotton is an Emeritus Professor at Stellenbosch University. He undertook a fellowship in Paediatric Infectious Diseases in Denver, CO between 1991 and 1994. He participated in several pivotal clinical trials in children, both on ART strategy (CHER), isoniazid prophylaxis and also ARV pharmacokinetics in children. Mark Cotton leads the South African component of PAVE (Paediatric HIV Elimination), funded by NIAID through the Martin Delaney Collaboratory and he is working on HIV remission studies in children. He was a member of the EPIICAL Collaboration for HIV remission between 2014 and 2023. Cotton was president of the World Society of Paediatric Infectious Diseases between 2019 and 2022 and now chairs its education committee. Since December 2022, he is chief editor of the Southern African Journal of Infectious Diseases.



## MARLÈNE BRAS

Marlène Bras has more than 14 years of experience in public health, research and management in the HIV field. She was trained at the Pasteur Institute (France) and holds a PhD in cellular biology from the Pierre and Marie Curie University (Paris VI, France). She was appointed as Director, HIV Programmes and Advocacy in September 2022 and is also the Executive Editor of the Journal of the International AIDS Society (JIAS). A basic scientist by training, Bras has worked across HIV disciplines from basic and clinical sciences to behavioural, epidemiology and implementation sciences. She oversees the Towards an HIV Cure programme of the IAS – International AIDS Society.



## MARY MAROVICH

Mary Marovich is currently a Medical Director in Infectious Diseases at BioNTech. She was the Director of the Vaccine Research Programme in the Division of AIDS at NIAID (2012-2023) leading the development, strategic planning and coordination of global clinical testing and preclinical research on HIV and TB preventative vaccines and biologics. The complex portfolio included novel vaccine candidates, monoclonal antibodies and adjuvants for pre-clinical research and translation to Phase 1-3 testing. During the SARS-2 pandemic, Marovich co-Chaired the Vaccine Development Team for



Operation Warp Speed and directed the clinical development of SARS-2 monoclonal Antibodies. Additionally, Marovich established a large Phase 3 trial of mRNA based COVID vaccines in PLWH in Sub-Saharan Africa studying vaccine efficacy and monitoring for SARS-2 viral persistence and evolution in immunocompromised populations with or without hybrid immunity. Previously, Marovich was the Chief of Vaccine R&D at the U.S. Military HIV Research Program, Walter Reed Army Institute of Research. There, she led an international HIV vaccine research programme testing multiple vaccine platform technologies as an investigator on multiple HIV and non-HIV vaccine studies. Marovich received her Medical Degree from Loyola University of Chicago, completed Internal Medicine and Infectious Disease training at the University of Colorado and the London School of Hygiene and Tropical Medicine and an Immunology fellowship in intramural NIAID. Marovich is a Professor of Medicine at the Uniformed Services Health Sciences Center in Bethesda, MD.




## **MASUZYO CHIRWA**

Masuzyo Chirwa is a medical doctor, epidemiologist, and clinical research fellow at the Centre for Infectious Disease Research in Zambia (CIDRZ). She is passionate about infectious disease epidemiology and the role of vaccines for prevention of diarrhoeal and respiratory diseases in young children. Her current work seeks to understand the epidemiology of Rotavirus, HIV and TB, assess promising candidate vaccines, and explore strategies to improve the performance of existing vaccines in high burden countries. She holds a Bachelor of Science, Bachelor of Medicine and Surgery from University of Zambia and a Master of Science in Epidemiology from the London School of Hygiene and Tropical Medicine.



## **MATTHEW ROMO**

Matthew Romo is a Clinical-Epidemiologic Investigator at the Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF) supporting the US Military HIV Research Program (MHRP) at the Walter Reed Army Institute of Research (WRAIR). In this position, he contributes to the scientific oversight and direction of epidemiologic studies and clinical trials in HIV, sexually transmitted infections, and other infectious diseases. He is an associate investigator for the African Cohort Study (AFRICOS) in Kenya, Nigeria, Tanzania, and Uganda and the Multinational Observational Cohort of HIV and other Infections (MOCHI) in Kenya, Uganda, and The Philippines. He conducts research on HIV testing, prevention, treatment, and cure, and frequently leverages implementation science methodologies and frameworks. He is a registered pharmacist and doctoral-trained epidemiologist.



## **MELISSA-ROSE ABRAHAMS**

Melissa-Rose Abrahams is a senior lecturer at the University of Cape Town, with a PhD in Medical Virology, her research focuses on characterising the HIV latent reservoir, specifically in African women, to inform strategies to reduce or eliminate this barrier to a cure. This work involves HIV reservoir sizing and sequencing in individuals on antiretroviral treatment (ART) using quantitative PCR, next-generation sequencing and phylogenetics.



## **MICHAEL LOUELLA**

Michael Louella has worked in HIV treatment research for 24 years, engaging communities affected by HIV in Seattle and across the U.S. in clinical trials by the ACTG Network towards the treatment and potential elimination of HIV. He joined the defeat HIV Martin Delaney Collaboratory as their Community Engagement Project Manager in 2013, focusing his engagement efforts on cell and gene therapies for HIV cure. He has served as a Steering Committee member for The Reunion Project since 2018, working to produce events for HIV long-term survivors throughout the U.S. Recently he joined the Global Gene Therapy Initiative, an alliance of key stakeholders including clinicians, scientists, engineers, advocates & community members brought together to enable access & implementation of gene therapies as curative medicines for presently incurable diseases in low- and middle-income countries.



## MICHAEL PELUSO

Michael Peluso is an infectious disease physician and researcher in the Division of HIV, Infectious Diseases, and Global Medicine at the University of California, San Francisco. His long-term focus has been on the chronic sequelae of HIV infection, including HIV-associated inflammation and the HIV reservoir. He has recently overseen the implementation of several clinical trials focused on HIV cure, including a combination trial of HIV vaccines, immunotherapies, broadly neutralising antibodies, and an analytic treatment interruption (ATI). He has worked closely with community advisory boards to develop guidance for how mitigate HIV transmission risk for ATI participants and how to safely carry out these studies.



## MICHELLE MUTHUI

Michelle Muthui's research background is in molecular biology and immunology, and she is currently working as an early-career postdoctoral research assistant at KWTRP. Her research interests revolve around understanding host-pathogen interactions and disease pathogenesis to develop health interventions. Muthui is currently working on research projects aimed at characterising the naïve immune repertoire of African populations as well as investigating novel strategies to developing HIV vaccines.



## MIKE MCCUNE

Mike McCune, MD, PhD is a renowned immunologist who began his medical career over four decades ago, treating people with AIDS at San Francisco General Hospital when the HIV epidemic first exploded onto the scene. He now leads the HIV Frontiers initiative at the Bill & Melinda Gates Foundation, which aims to discover, develop, and deliver an HIV cure for global implementation.



## MILTON MATHONSI

Milton Mathonsi, a member of the PHRU CAB and CSS Co-chair, currently resides in South Africa, specifically in Johannesburg Soweto Region D. His journey commenced as a CAB member in February 2013. In his capacity, he actively engages in various activities aimed at serving his community and constituency.

One of Mathonsi's primary responsibilities is to disseminate information within his community regarding the clinical research conducted at PHRU. This involves educating community members about ongoing studies, preparing them for the recruitment processes, and ensuring they understand the benefits of participating in research. He works diligently to mobilise and identify suitable operational sites, collaborating closely with local organisations, churches, traditional healers, and other stakeholders to achieve positive outcomes for the community.

Mathonsi's commitment to community development is evident through his efforts to bridge the gap between PHRU and the community. He organises events and workshops to inform and involve community members in research activities, employing effective sensitisation strategies to ensure sustained engagement and understanding.

His engagement strategies focus on three key areas:

- Organising workshops and events to train and inform the community and partners,
- Educating them about HIV/AIDS and non-communicable diseases, and
- Encouraging participation in clinical trials through collaborative efforts with partners and community members.

In conclusion, Mathonsi believes his extensive experience and active involvement in the community make him a valuable asset to any structure, including the Strategic Working Group (SWG). He sees his participation in such groups as an opportunity to further enhance his understanding of community engagement and contribute to its success.



## MOHERNDRAN ARCHARY

Moherndran Archary is an Honorary Professor in the School of Clinical Medicine and a Paediatric Infectious Disease Specialist in the Department of Paediatrics and Child Health at the University of KwaZulu-Natal/King Edward VIII Hospital and NIHR Global Research Professor. Archary specialises in the management of children with infectious diseases in resource-limited settings. As part of his PhD thesis, he investigated the pharmacokinetics

of antiretroviral drugs in severely malnourished HIV infected children. His research interests include antiretroviral and antituberculosis drug therapeutics, drug resistance, and the optimal timing of antiretroviral therapy initiation in the developing world. He serves on several local, national and international committees.



### **MONIQUE NIJHUIS**

Monique Nijhuis obtained her PhD in 1999 at the University of Utrecht on the investigation of the impact of antiretroviral resistance on HIV fitness. Following postdoctoral research training she initiated a research line at the interface between fundamental and clinical research and became an honourable Professor of the University of the Witwatersrand in Johannesburg and an Associate Professor of Virology at the University Medical Center Utrecht in The Netherlands. Her research interest is centred on (1) Viral reservoirs and eradication, including stem cell transplantation and gene-therapy and (2) Mechanisms of viral resistance and evolution.

She is heading the international multidisciplinary Spiral consortium investigating HIV cure strategies with a specific focus on sub-Saharan Africa, is a member of the IAS HIV Cure International Scientific Working Group, Associated Editor of Retrovirology and published >100 original papers in peer reviewed journals and has guided many students, PhD students and Postdoctoral Fellows.




### **MOSES SUPERCHARGER NSUBUGA**

Moses Supercharger Nsubuga is a Ugandan musician radio DJ and person openly and positively living with HIV since 1994. He heads a community-based organisation called Joint adherent brothers and sisters against AIDS which promotes literacy of HIV treatment, prevention tools and research, he is the founder and chair of the first global HIV ARTSEUM under construction in Uganda. He represents people living with HIV on GGTI, IAS Cure advisory board, ACTG CSS, INSIGHT, STRIVE and a member of the Joint clinical research Centre CAB, Nsubuga is an AVAC alumnus and his hobbies are food, music, traveling and making lively HIV presentations.



### **NOMONDE BENGU**

Nomonde Bengu is a dedicated medical professional with extensive experience in paediatrics, particularly in neonatal care, HIV management, and paediatric neurology. With a solid educational background from reputable institutions in the United States, Nomonde has been instrumental in various medical roles, demonstrating leadership and expertise throughout her career. Currently serving as a Sessional Medical Doctor at Queen Nandi Regional Hospital, Nomonde continues to make significant contributions to the field of paediatrics and medical research.



### **NOMUSA NTULI**

Nomusa Ntuli is born and raised in KwaZulu-Natal, South Africa. She is a mother, a wife and a Professional Nurse currently practicing at the FRESH clinic. She holds 17 years' experience both in the public and private sector.



### **NYANDA NTINGINYA**

Nyanda Elias Ntinginya is a Director of Research Coordination and Promotion and Principal Research Officer at the National Institute for Medical Research (NIMR) in Tanzania with a background in Medicine. With over 16 years of experience, he is a seasoned expert in medical research that has served in diverse roles as a Sponsor representative, Principal Investigator, Research Leader and Coordinator at institutional, national and international levels. His expertise extends across cross-functional, multicultural and international environments. His abiding interest lies in leveraging the potential of research to tackle the pressing global health challenges, ultimately adding value to humanity. He has experience in clinical trials (drugs and vaccines), implementation, operational and diagnostic studies especially on TB, HIV and comorbidities as well as research of emerging diseases and NCDs (selected) with over 80 publications on related areas in peer reviewed journals. His commitment and interests extend to improving the research landscape and strengthening health systems to produce

evidence that guides policy and practice. He is passionate about mentoring and building the capacities of early and mid-career researchers aiming to cultivate future generation of researchers. He is a member and/or co-leader of numerous national and international research networks, technical working groups and committees including at the Tanzanian Ministry of Health. He was a member in the Presidential Special Advisory Technical Committee on COVID-19 in Tanzania.

Before his recent appointment at the national level, he has been leading the Mbeya Medical Research Centre which is also under the Tanzanian National Institute for Medical Research (NIMR) offering invaluable strategic research leadership since 2016.



## **NYARADZO MGODI**

Nyaradzo Mgodzi is Deputy Editor of the Journal of the International AIDS Society and Associate Editor at Frontiers in Global Reproductive Health – HIV and STIs. She is also a board member for the Medical Research Council of Zimbabwe. As a clinical pathologist and clinical trials specialist with over 15 years of experience, she has conducted clinical trials for HIV prevention in women of reproductive age in Sub-Saharan Africa. Her experience includes the implementation of several trials assessing acceptability, safety and effectiveness of oral PrEP, vaginal microbicides, the Dapivirine vaginal ring, long-acting injectable PrEP and broadly neutralising antibodies for HIV prevention in African women at risk for HIV. She has provided comprehensive SRHR services including contraception to all her study cohorts.

She was protocol co-chairperson for HVTN 703/HPTN 081 study, also known as Antibody Mediated Prevention (AMP) and of MTN 025/HOPE study. Nyaradzo serves as a member of the HPTN Executive Committee, as a scientific reviewer for the Medical Research Council of Zimbabwe and has served as a technical advisor for the Zimbabwe Population-based HIV Impact Assessment (ZIMPHIA) survey. She is a member of the Policy and Implementation Steering Committee for the Global Evaluation of Microbicide Sensitivity (GEMS) project, HIVR4P Programme Organising Committee and also served as Conference Advisory Committee member for International AIDS Society (IAS). Mgodzi attained a MBChB and a Masters in Medicine in Histopathology from the University of Zimbabwe.



## **OMU ANZALA**

Omu Anzala is a Professor of Virology and Immunology in the Department of Medical Microbiology; Senior Research Scientist at KAVI – Institute of Clinical Research (KAVI - ICR), University of Nairobi, Kenya. He holds a degree in MBChB from the University of Nairobi, Kenya; a Diploma in Epidemiology - Tufts University in USA; a PhD in virology and immunology - University of Manitoba, Canada and Postdoctoral Fellow at Molecular Immunology Institute, Institute of Molecular Medicine (IMM), Oxford University, UK.

Anzala is the leading HIV vaccine investigator in Kenya and was one of the founders of KAVI in the year 1999 as the HIV Vaccine research Unit in Kenya and moving it to its current status as an Institute of Clinical Research in 2013. He was co-PI of the first HIV vaccine trial in Kenya, the second in Africa, using a DNA plasmid. He has subsequently been PI or co-PI for 11 IAVI-funded HIV vaccine trials in adults and the first paediatric HIV vaccine trial in Kenya. Additionally, Anzala has been the Principal Investigator for the just completed Phase I & Phase II Candidate Ebola Vaccine Trials which were funded by Janssen & Janssen.

Anzala has a diverse background in HIV prevention research and his research has focused on the immunological and genetic correlates of long-term survival and immunologic non-progression among HIV-infected sex workers in Kenya. Related experience includes a RCT of azithromycin prophylaxis for STI and HIV, an intermittent PrEP RCT as well as multiple epidemiology studies in at-risk populations including acute HIV infection, mucosal immunology and broadly neutralising antibody identification in HIV- infected subjects.


In addition to HIV research Anzala has pioneered research in One health, looking at infectious elements at the human-animal interface and bringing together collaborators from Europe, India, and other African Countries, Anzala has trained in vaccinology with WHO and serves as a member of the Ministry of Health, Vaccination Experts Committee; National Polio Expert Committee, National Vaccine Safety Advisory Committee (all in Kenya) and African Vaccine Manufacturing Initiative (South Africa). He is a co-chair of WHO-African Advisory Committee and Vaccine Safety and the Country PI of the WHO

Covid Solidarity Trial. He is a Member of National COVID -19 TASK force and a team leader of National COVID-19 Case management, Research and modelling consortium. He has authored and co-authored over 120 peer- reviewed publications, supervised and mentored over 23 masters and 6 PhD students to successful completion of their studies and continues to do the same for many more.



## **PABLO BELAUNZARÁN-ZAMUDIO**

Pablo Belaunzarán-Zamudio is a researcher and medical officer affiliated with the National Institute of Allergy and Infectious Diseases in Bethesda, MD, USA since September 2019. He works in the Division of AIDS, Therapeutics Research Program. His portfolio includes clinical trials testing HIV therapeutic and cure strategies, strategies to improve ART adherence, and interventions to improve the health of people receiving HIV care. Prior to this, he was the Head of the HIV Clinic and Researcher in Medical Sciences at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán in Mexico from May 2013, to September 2019. His educational background includes a Ph.D. in International Health from the Johns Hopkins Bloomberg School of Public Health, a Master's in Sciences from the University of Oxford, and specialisation in Infectious Disease and Internal Medicine from the Universidad Nacional Autónoma de México and the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Additionally, he holds a Diploma in Tropical Medicine & Hygiene from the London School of Hygiene and Tropical Medicine. Belaunzarán-Zamudio's research contributions span various topics related to HIV, epidemiology, and the impact of late HIV diagnosis in Latin America.



## **PERVIN ANKLESARIA**

Pervin Anklesaria serves as the Deputy Director at the Bill & Melinda Gates Foundation (BMGF), where she spearheads the HIV vaccines and biologics prevention initiatives. Since joining BMGF in 2012, her work has primarily centred on the development of prophylactic HIV vaccines and biologics. The foundation's vaccine programme invests in vaccines aimed at eliciting broadly neutralising antibodies (bnAbs), as well as vaccines that stimulate Class 1 restricted and/or MHCE restricted CD8 T cells. Furthermore, the BMGF HIV team supports the use of bnAbs and bi-specific antibodies, along with the optimisation of bnAbs for HIV prevention.

Prior to her tenure at the BMGF, Anklesaria held a leadership role at Targeted Genetics Corporation from 1993 to 2009. There, she led the regulatory team and clinical developments of AAV vectors for inherited diseases and explored their application in HIV vaccines, in collaboration with IAVI and the NIH/DAIDS. Following this, she joined IAVI for two years as a project director and senior advisor, focusing on various HIV vaccine candidates.

Anklesaria obtained her Ph.D. from the University of Mumbai in India, subsequently embarking on a productive research career in hematopoietic stem cell differentiation and the application of emerging gene therapy technologies at the UMass Memorial Medical Center in Massachusetts.



## **PETER KIM**

Peter Kim, M.D., is the Director of the Therapeutics Research Programme at the Division of AIDS, National Institute of Allergy and Infectious Diseases. He currently oversees a broad portfolio of research grants and contracts involving diagnostics and therapeutics for HIV, tuberculosis, and other HIV related co-infections. His primary areas of expertise and interest include clinical TB and HIV drug development and treatment strategies, as well as TB biomarkers and diagnostics.

He is a U.S. Board certified Infectious Diseases specialist. He received his bachelor's degree in Public Health from Johns Hopkins University and his medical degree from the University of Maryland School of Medicine. From there he went on to complete his training in Internal Medicine and Infectious Diseases at the Washington Hospital Centre, Georgetown University, in Washington, D.C



## **PHILIP GOULDER**

Philip Goulder is a Professor of Immunology at the University of Oxford in UK. He read Zoology at Oxford University and then Medicine at Cambridge University before specialising in Paediatrics. His research centres on mechanisms of immune control of HIV infection in children and adults, on defining the mechanisms by which paediatric HIV cure can be achieved, and on the impact of early life immune sex differences on paediatric cure potential. Based at the Peter Medawar Building in Oxford, this work is focused on the HIV epidemic in South Africa through long-term links in Kimberley and in Durban with the Doris Duke Medical Research Institute at the University of Kwa-Zulu-Natal, CAPRISA and the African Health Research Institute (AHRI). This work is also supported by long-standing collaborations with colleagues at the Ragon Institute of MGH, MIT and Harvard in Boston where Goulder is a Research Associate.




## **QIAOLI PENG**

Qiaoli Peng is an Associate Chief Physician in the Department of Infection and Immunology at the National Clinical Research Centre for Infectious Diseases, located at the Third People's Hospital of Shenzhen and the Second Affiliated Hospital of Southern University of Science and Technology in Shenzhen, China. As a doctor, she specialises in antiretroviral therapy and the diagnosis and treatment of opportunistic infections. Her current research interests are focused on two areas: 1) understanding the pathogenesis of HIV and the mechanisms underlying naturally occurring HIV control models such as elite controllers or post-treatment controllers; and 2) clinical immunotherapy for curing HIV. Peng is currently serving as a principal investigator assistant for a phase 1 clinical trial of a novel PD1-based candidate therapeutic HIV vaccine in China.




## **RAJESH GUPTA**

Rajesh Gupta is Senior Vice President of the Global Health Portfolio and Public-Private Partnerships and also Interim Head of Business Development at Vir Biotechnology. His responsibilities include advancing Vir's research and development, access, and policy efforts aimed at treating and preventing infectious diseases in low- to middle-income countries (LMICs) through Vir's monoclonal antibody and viral vector vaccine platforms. In addition, he helps lead Vir's pandemic preparedness strategy through its public-private partnerships and business development through its industry alliances. A physician-epidemiologist by training, Gupta has spent nearly 20 years in global health and infectious diseases working at the intersection of product development, programme implementation and health policy. Gupta's experience ranges from molecular diagnostic development in HIV and other retroviruses at the US Centers for Disease Control and Prevention, health services delivery in LMICs with Partners in Health, policy development in tuberculosis (TB) and HIV at the World Health Organization, investments and grant management in pandemic preparedness at Google.org, and the development and approval/authorisation of therapeutics for multidrug-resistant TB and COVID-19, respectively, with Otsuka Pharmaceutical Company and Vir. In addition, Gupta has held faculty positions at Stanford Medical School and Harvard Medical School, and has authored over 50 publications in leading academic journals. He received his MD and MS from Stanford University, MPH from Yale University, and BS and BA from Tulane University.



## **RAZIA HASSAN-MOOSA**

Razia Hassan-Moosa is a senior research clinician at the Centre for the AIDS Programme of Research in South Africa (CAPRISA). She has a master's in public health and has 10 years of clinical research experience which has included work in the field of paediatric infectious disease and paediatric vaccines as well as HIV-TB co-infection treatment studies, TB prevention and TB vaccine trials. She has contributed to scientific publications as co-author and has presented at both national and international conferences. She is an experienced safety clinician serving as chair of the internal protocol and safety review team. Hassan-Moosa currently works as a senior research clinician in the CAPRISA HIV Vaccine and Pathogenesis Programme. Her current research work involves first in human clinical trials investigating HIV prevention vaccines and broadly neutralising monoclonal antibodies.



## **RICCARDO MADDALOZZO**

Riccardo Maddalozzo works as a Project Manager, Capacity Development and Engagement at the International AIDS Society where he oversees the Towards an HIV Cure and Mark Wainberg Fellowship programmes focusing on capacity building for HIV researchers, advocates and service providers. He holds a bachelor's degree in international relations and geography from Macalester College in the US and a master's in global health from the University of Copenhagen in Denmark.



## **ROGER SHAPIRO**

Roger Shapiro is a Professor of Immunology and Infectious Diseases at the Harvard T.H. Chan School of Public Health. He has worked for over two decades in Botswana, performing clinical trials and nationwide surveillance to improve health outcomes for HIV-infected pregnant women and their children. His current research focus is to understand the relationship between antiretroviral drugs used in pregnancy and adverse birth outcomes, and to study novel diagnostic and treatment strategies for HIV-infected children.

In Botswana, Shapiro has pioneered new strategies to prevent vertical transmission of HIV, provided early data to support antiretroviral treatment strategies that were safe enough to allow breastfeeding, and evaluated risks for morbidity and mortality among HIV-exposed infants. He is currently principal investigator or co-principal investigator for research programmes that perform: 1) surveillance at 18 sites in Botswana evaluating the relationship between antiretroviral therapy and adverse birth outcomes, including congenital abnormalities; 2) a multi-site study evaluating the safety, efficacy, viral reservoir reduction, and immunologic profiles following very early antiretroviral treatment initiation for HIV-infected infants; and 3) a clinical trial evaluating two broadly neutralising monoclonal antibodies (bNAbs) as a novel treatment strategy for HIV-infected children. He supports additional research in Botswana as the principal investigator of a Fogarty award, through a successful partnership between Harvard-affiliated hospitals and the Scottish Livingstone Hospital in Botswana, and as a research mentor bridging Boston and Botswana sites. Shapiro's research has been used to direct health policy in Botswana and internationally, and through this work he has served as a scientific advisor to the World Health Organisation for the development of guidelines for HIV prevention, antiretroviral treatment, and infant feeding.



## **RONALD MOSES GALIWANGO**

Ronald Moses Galiwango is a dedicated medical professional with a passion for advancing healthcare and scientific research. His journey has taken him across several institutions, where he has honed his expertise in various fields.

Galiwango pursued doctoral studies in immunology at the University of Toronto. His research explored the role of penile circumcision in modification of immunological and microbiome determinants of HIV susceptibility in the male genital tract and how this can inform development of alternative HIV prevention options for men declining circumcision.

At Johns Hopkins University, Galiwango was equipped with didactic courses that enriched his understanding of the molecular, microbiological, and immunological basis of disease pathogenesis and how this knowledge can be harnessed toward better treatment and cure. He acquired essential skills to explore infectious diseases, host-microbe interactions, and cutting-edge research techniques. His master's thesis focused on using nucleotide sequencing to characterize HIV-1 genetic variation in foreskin and blood from subjects in Rakai Uganda.

Galiwango's foundational education took place at Makerere University Kampala, Uganda. Here, he earned his bachelor's degree in human medicine and surgery and this training covered clinical medicine, surgical techniques, and patient care.

As the Laboratory Director at the Rakai Health Sciences Program, Galiwango plays a crucial role in advancing professional laboratory practice through timely and quality clinical and research sample testing. Alongside this, he reviews patients and conducts several studies related to infectious diseases, product/assay validation, in collaboration with multidisciplinary teams.



## **RONIVIN PAGTAKHAN**

Ronivin Pagtakhan is the founder of LoveYourself, an organisation that has risen to become the leading organisations in HIV/sexual and mental health, awareness, testing and treatment in the Philippines.

Pagtakhan is a doctor and a nurse. He has a PhD, a Master's in nursing and BS Nursing and Medicine degree from UP Manila. He graduated top of his class and ranked 4 in the national board exam for nursing. He was a nurse educator and practitioner prior to starting LoveYourself.

He was recognised as one of The Outstanding Young Men (TOYM) Philippines for Youth Leadership and Outstanding Young Person of Taguig in 2016 and 2017 and last year 2018, he was recognised as one of the outstanding young persons of the world (TOYP) for Humanitarian Leadership.

Pagtakhan believes that self-worth is an empowering tool that helps the most affected populations such as males who have sex with males gain confidence and, in turn, adopt safer sex practices. He is a public health champion that is bringing the community together with his passion and optimism to rally against the spread of HIV.

Under Pagtakhan's leadership, LoveYourself has established 25 clinics which rank as the top most visited in the country for HIV screening; one of the clinics is the first transgender health clinic in the Philippines called Victoria by LoveYourself to assist in transitioning counselling and HRT.

LoveYourself assists 30-50k people yearly and around 50% of the newly diagnosed persons living with HIV in Metro Manila (with 7,300 currently on LY treatment programme) and 20% in the Philippines come from LoveYourself clinics - a feat made more impressive considering that the non-profit organisation is mostly powered by its 2000 strong volunteers.



## **ROSE NABATANZI**

Rose Nabatanzi is currently a lecturer in the department of Immunology and Molecular Biology as well as a laboratory scientist in the department of Immunology and Molecular Biology Makerere University College of Health Sciences. She has 18 years of experience in biomedical HIV research and academia. She is interested in conducting translational research in Immunology of infectious diseases particularly HIV and its co-infections. She holds the European & Developing Countries Clinical Trials Partnership (EDCTP) career development award and the CFAR AFRICURE award to look at the characteristics of the HIV-1 reservoir among ART-treated HIV infected individuals in Uganda. She would like to explore potential drivers of persistent immune abnormalities looking at the role played by the HIV-1 reservoir among antiretroviral therapy (ART) treated people. She is focusing on utilising her research experience to answer questions relevant to improvement of HIV treatment outcomes, remission and cure.



## **RUJEKO SAMANTHIA CHIDAWANYIKA**

Rujeko Chidawanyika is a Research Associate at Africa Health Research Institute. She holds a PhD in Gender Studies (University of KwaZulu-Natal), M.Sc. in Development Studies (University of the Free State) and BA. in Psychology (University of Zimbabwe). Her research interests are in the thematic areas of social science and research ethics related to global health. Her research focuses on social and behavioural research in HIV cure science, HIV/AIDS health care services, health systems strengthening and HIV/AIDS prevention among pregnant women, key and high-risk populations. With over 10 years' experience, Chidawanyika actively contributes to various multidisciplinary projects with various national and international collaborative networks where she also mentors junior staff and students. In her current research, she is investigating the public understanding of HIV cure research in uMkhanyakude District, KwaZulu-Natal, South Africa.




## **SAMANTHA FRY**

Samantha Fry is a paediatrician actively involved in research at FAMCRU for the past 8 years. The FAMily Centre for Research with Ubuntu is a Stellenbosch University affiliated clinical trials unit with a focus on adult and paediatric infectious diseases, in particular HIV and TB. As a clinical trial lead, Samantha is involved in investigating novel HIV treatment and HIV CURE strategies including therapeutic vaccines and long-acting injectable antiretroviral therapy. Samantha has a keen interest in neurodevelopment,



having particularly as it relates to HIV and the developing brain as well as neurocognitive changes associated with antiretroviral therapy (ART) interruption. Her recent work in the Healthy Babies study, assessed neurodevelopmental effects of in utero and post-natal maternal ART exposure.




## **SARAH FIDLER**

Sarah Fidler works as a clinical doctor and senior academic at Imperial College London, where her main focus of research is the strategic use of antiretroviral therapy and novel innovative therapies towards an HIV cure. She led the international randomised SPARTAC trial testing the use of short-course ART in acute infection. Its findings led to a large cluster randomised trial among urban communities in Zambia and South Africa (HPTN 071 PopART), which tested the impact of a universal HIV test-and-treat programme to reduce HIV incidence.

Through the HIV CHERUB UK collaboration, with colleagues in Oxford, Kings, Cambridge and UCL, Sarah led several observational studies exploring measures of the HIV reservoir and immune responses among people living with HIV (HEATHER, PITCH). The team works very closely with community advocates, and public engagement is a core part of the CHERUB approach. More recently, the collaboration supported clinical trials of ART plus new therapies towards a cure for HIV. The RIVER trial explored a “kick and kill” approach among treated primary HIV infection. Currently the consortium is enrolling into a double blinded randomised trial testing HIV-specific broadly neutralising antibodies (RIO) to control HIV, instead of antiretroviral therapy. The RIO trial is in partnership with the University of Oxford and Rockefeller and is recruiting across the UK.

Fidler provides clinical care to young adults with perinatally acquired HIV and a tertiary referral service for individuals with indeterminate HIV tests and spontaneous viral controllers.



## **SERENA SPUDICH**


Serena Spudich is Gilbert H. Glaser Professor of Neurology, Chief, Division of Neurological Infections and Global Neurology, and Co-Director, Center for Brain and Mind Health at Yale University. Her clinical and translational research explores effects of HIV and SARS-CoV-2 infection in the nervous system, focusing on establishment of local viral infection and CNS injury during acute infection, effects of interventional strategies on viral pathogenesis and HIV persistence in the central nervous system, and viral neuropathogenesis during therapy. She collaborates with investigators from multiple disciplines in studies in the United States and in international settings, especially in Bangkok, Thailand, exploring questions of inflammation, injury, and viral reservoirs within the central nervous system. She co-leads the International NeuroHIV Cure Consortium, serves on the US DHHS Antiretroviral Treatment Guidelines Committee, CROI Programme Committee, has been active in the International AIDS Clinical Trials Group, and since 2021 has been co-Chair of the Steering Committee for the \$1.1 billion NIH RECOVER study on long COVID. She also is a neurology physician who clinically cares for patients with viral infections and neurological disorders at Yale.



## **SHARON LEWIN**


Sharon Lewin is an infectious diseases physician and basic scientist, who is internationally renowned for her research into all aspects of HIV disease and specifically in strategies to achieve an HIV cure. She received her medical degree and PhD from Monash University, Melbourne, Australia and post-doctoral training at Rockefeller University, New York. She is the inaugural Director of the Doherty Institute, a joint venture of the University of Melbourne and Royal Melbourne Hospital and Melbourne Laureate Professor of Medicine at the University of Melbourne, Melbourne, Australia. She is also the inaugural director of the Cumming Global Centre for Pandemic Therapeutics, a new centre at the Doherty Institute established by a philanthropic gift of \$250 million from Canadian philanthropist Geoff Cumming and \$75 million from the Victorian government. She heads a laboratory of 25 scientists and clinicians working on basic and translational research and early phase clinical trials aimed at finding a cure for HIV. She has published over 350 papers and is a Clarivate hi-citation researcher since 2019. She has received continuous funding from the NHMRC since 1993 and from multiple international funding agencies including the National Institute for Health and the American Foundation for AIDS Research. In 2019, She was appointed an Officer of the Order of Australia (AO) in

recognition of her distinguished service to medical research, and to education and clinical care, in the field of infectious diseases, particularly HIV and AIDS. She is the elected President of the International AIDS Society (2022-2024), the largest professional society representing people working in HIV medicine and has over 17,000 members.



## **SIMANI GASEITSIWE**

Simani Gaseitsiwe is a molecular virologist based at Botswana Harvard Health Partnership (BHP). He serves as a research associate at BHP and at Harvard T. H. Chan School of Public Health. His research focuses on understanding the molecular epidemiology of various pathogens of public health interest including HIV-1, HBV, SARS-CoV-2, HPV and M. tb in Botswana and globally. Gaseitsiwe has graduated over 20 MPhil and PhD students and is currently supervising 12 graduate (MPhil and PhD) students.



## **SIPHO KHUMALO**

Sipho Khumalo has served on the SANTHE Secretariat since the establishment of the network in 2016. In this role, he provides research management support in the areas of finance, administration and IT. Khumalo holds a BSc Degree in Chemistry and Geology with the University of Cape Town in the Western Cape, South Africa. He has also acquired certificates in IT and project management, grants management, HR support, and financial grants. His past roles have included Research Assistant, Administration Manager and Project Coordinator at a hospital and various non-profit organisations.



## **STEVEN DEEKS**

Steven Deeks is a Professor of Medicine at the University of California, San Francisco. He is an expert on HIV and its impact on health during antiretroviral therapy. In early 2020 his team leveraged his HIV programme (SCOPE) to implement one of the first prospective studies aimed at defining the natural history, biology and treatment of Long COVID (LIINC). Deeks has published over 700 peer-reviewed articles, editorials and invited reviews on these and related topics. He is the contact principal investigator (PI) of DARE (the Delaney AIDS Research Enterprise), an NIH-funded international collaborative aimed at developing a cure for HIV infection. He is also the contact PI for one of the adult cohort sites within RECOVER, a national Long COVID research programme. Deeks was elected to the American Society for Clinical Investigation (ASCI) and the Association of American Physicians (AAP) and serves on the scientific advisory board for Science Translational Medicine. He is listed annually as one of the world's most cited scientists for the past several years. In 2022, he received the Lifetime Achievement in Mentoring Award from UCSF. He maintains a primary care clinic for people living with HIV.



## **SUSAN BARNETT**

Susan Barnett is a Senior Programme Officer, HIV Vaccine Product and Clinical Development, on the TB & HIV Team in the Global Health Division at the Bill & Melinda Gates Foundation. In this capacity, Barnett is responsible for a portfolio of investments, and scientific interactions with investigators on funded research and development projects related to HIV vaccines and biologics, and during the pandemic, for several of the foundation's COVID-19 vaccine investments in vaccine platform and product development. Prior to coming to the foundation, Barnett was employed at GSK Vaccines, and prior to that, Novartis Vaccines, where she served as a Senior Director in Research & Development. During her time in industry, Barnett was one of the earliest investigators to evaluate novel adjuvants in combination with HIV Env proteins, and to apply nucleic acid vaccine approaches to HIV Env immunogen discovery, exploring the use of DNA prime plus Env protein boost vaccine regimens for HIV at Chiron Corporation in the mid-90s, and then working with the team at Novartis Vaccines that first explored the use of self-replicating mRNA (SAM) vaccines for HIV and multiple infectious disease targets.



## **TATENDA NYAMANDI**

Tatenda Nyamandi is a Senior Regulatory officer at the Medicines Control Authority of Zimbabwe (MCAZ), Pharmacovigilance and Clinical Trials Division. Nyamandi has 10 years' experience in clinical trials. His roles at the MCAZ include review of clinical trial applications, clinical trial monitoring reports such as annual reports, protocol deviations and DSMB reports. Nyamandi is also involved in inspection of clinical trials and facilities.

He is a holder of a Bachelor's Honors Degree in Pharmacy from the University of Zimbabwe. Nyamandi is also a Global Health Protection Programme (GHPP) Vacc-Train fellow hosted by the Paul-Ehrlich-Institute of Germany. He is also currently studying an MSc in Applied Pharmaceutics in Regulatory Affairs offered by the University of Zimbabwe.

Nyamandi has been involved in several clinical trials capacity building programmes and consultancies for several African countries. Nyamandi has also participated and presented in various clinical trials workshops and forums locally, regionally, and internationally.

During his spare time Nyamandi likes reading novels and watching football.




## **TERESIA MUHOMAH**

Teresia Muhomah is a postdoctoral scientist working at KAVI- Institute of Clinical Research, University of Nairobi, Kenya. Her research work focuses on two main areas. The first research area is focussed on characterising the HIV reservoir in multiple anatomical compartments in the Kenyan population. She hopes that the research findings provide valuable insights that will inform HIV cure strategies. The second research area focuses on tissue immunology where she is interested in understanding the mucosal factors that influence HIV infectivity particularly in the female genital tract. Through her work she aims to contribute to efforts aimed at generating a global HIV vaccine and cure. She is an alumnus of the IAS Research-for-cure Academy and IAVI Leadership Development Program. She is also a recipient of the ADVANCE Independent Investigator Research grant (2023- 2005) and HIV Research Trust Scholarship (2023- 2024). She holds a Ph.D. from Okayama University, Japan, where she focused on gut microbiota- immune interactions.



## **THANDI ONAMI**

Thandi Onami is a Senior Program Officer on the HIV Vaccine Team at the Bill and Melinda Gates Foundation, with a portfolio of work focused on evaluating candidate vaccines in pre-clinical models for potential advancement to clinical studies. Prior to joining the foundation, she served as an Immunologist at the Division of AIDS (DAIDS) at the National Institutes of Health (NIH), in the Laboratory Sciences Team in the Vaccine Research Program. In that capacity she supported glycomics and mucosal immunology programmes in HIV vaccine research and clinical trials. Before NIH, she was an Assistant Professor in the Department of Microbiology at the University of Tennessee in Knoxville where her research lab focused on the role of glycosyltransferases in T and B cell immunity to viruses, and where she taught classes in immunology, microbiology, and global health.



## **THUMBI NDUNG'U**

Thumbi Ndung'u is interested in understanding antiviral immune mechanisms and viral adaptation in HIV-1 subtype C infection as a pathway to vaccine development. His work has focussed on understudied populations and viral strains in resource-limited, high burden settings where knowledge of the role of antiviral immune responses, viral strains and associated genetic factors is likely to yield the greatest impact in terms of biomedical interventions like vaccines. Thumbi's early work addressed the lack of biological tools for HIV vaccine and pathogenesis research on HIV-1 subtype C, the predominant subtype globally and in southern Africa. He generated and characterised the first infectious molecular of HIV-1 subtype C from primary isolates, and constructed the first infectious subtype C envelope-derived simian-human immunodeficiency virus able to replicate in rhesus macaque peripheral blood mononuclear cells. These tools were deposited in the NIH AIDS reagent program and remain available to researchers. The tools have facilitated in vitro and animal model studies of HIV-1 subtype C biology and vaccine development research.

Ndung'u also actively participates in the training of graduate and postdoctoral researchers and has a special interest in capacity building for biomedical research in Africa. He is director for basic and translational science at AHRI, and a member of AHRI faculty. He is an investigator and Max Planck Institute for Infection Biology Research group leader. He is also a University of KwaZulu-Natal (UKZN) Professor and Victor Daitz Chair in HIV/TB Research, adjunct Professor at the Harvard School of Public Health, the scientific director at UKZN's HIV Pathogenesis Programme, the programme director for

the Sub-Saharan African Network for TB/HIV Research Excellence (SANTHE) and is the South African research chair in systems biology of HIV/Aids.



## **TREVOR CROWELL**

Trevor Crowell is Director of the Clinical Research Directorate supporting the U.S. Military HIV Research Program, Emerging Infectious Diseases Branch, and other components of the Walter Reed Army Institute of Research. He is also an Associate Professor in the Division of Infectious Diseases at the Uniformed Services University and has an adjunct appointment at Johns Hopkins University School of Medicine. His research includes observational studies of HIV with a focus on events during acute and early infection as well as clinical trials of novel interventions to induce HIV remission. He is protocol chair or vice-chair for several multinational studies in these areas coordinated by the Advancing Clinical Therapeutics Globally (ACTG) network. Crowell has authored over 140 peer-reviewed original research publications. He currently serves as a Deputy Editor for the Journal of the International AIDS Society, on the editorial boards for AIDS and AIDS Research and Therapy, and as a member of the Strategic Advisory Committee for the Africa Centres for Disease Control and Prevention. Crowell received his M.D. from the University of Southern California Keck School of Medicine and his Ph.D. in Clinical Investigation from the Johns Hopkins Bloomberg School of Public Health. Crowell is a Fellow of the Infectious Diseases Society of America.



## **UDOM LIKHITWONNAWUT**

Udom Likhitwonnawut has been working as a consultant for AVAC in Thailand for community engagement on HIV research since 2012. His work with AVAC is to promote community participation in HIV research and advocacy for GPP implementation in the country. He is also a member of the National Subcommittee on HIV Vaccine representing the Thai NGO Coalition on AIDS (TNCA), the national umbrella organisation for HIV/AIDS-related non-governmental organisations. Likhitwonnawut is one of the founders of Thailand national CAB (NCAB) on HIV research which was formed in 2013 by selected members of 5 existing institutional CABs in the country. In July 2023, he was appointed a member of Community Liaison Subcommittee (CLS) for CROI (Conference on Retroviruses and Opportunistic Infections).



## **VICTOR SINI**

Victor Sini is a seasoned neurologist who coordinates the HIV/AIDS comprehensive treatment centre at the General Hospital of Yaoundé. He also serves as a lecturer of neurology at the ISTM, University of Douala.



## **VICTORIA KASPROWICZ**

Victoria Kasprovicz earned her master's degree in molecular and cellular biochemistry, followed by a doctoral degree in clinical medicine, at Oxford University. She worked as a postdoctoral fellow at Harvard University and was subsequently promoted onto the faculty. Since 2008 Victoria has been actively engaged in research and scientific capacity strengthening efforts in Africa where she has worked as Director of Education and Training for the KwaZulu-Natal Research Institute for TB and HIV (K-RITH), and most recently as Head of Programmes for the Sub-Saharan African Network for TB/HIV Research Excellence (SANTHE). SANTHE is currently based at 7 institutes in 8 African countries (South Africa, Cameroon, Botswana, Rwanda, Zambia, Kenya, Uganda and Zimbabwe). Her most recent research aimed to identify biomarkers for TB, guide the design of novel immune-based TB diagnostics, and better understanding the impact of HIV on the immunological response to TB in patients infected with both pathogens. She has a special interest in developing partnerships to enhance HIV and TB research on the continent, strengthening researcher engagement with local communities and other stakeholders, and sharing the learning around research capacity strengthening efforts. She is helping to establish the Enhancing Scientific Capacity for Africa through Learning And Teamwork in monitoring and Evaluation (ESCALATE) network.



## **VIOLET KORUTARO**

Violet Korutaro is a Ugandan medical doctor and research investigator dedicated to improving maternal and child health. She works at the Baylor College of Medicine Children's Foundation-Uganda (Baylor-Uganda) Clinical Research Site (CRS # 31798).

She started her academic journey at Makerere University, where she earned a Bachelor's degree in Medicine and Surgery (MBChB) in 2004. Driven by her passion for public health, she pursued further studies at the University of London, obtaining a Master's degree in Public Health with a specialisation in Health Promotion in 2013. She also completed a postgraduate project planning and management skills diploma from the Uganda Management Institute in 2017.

Before her current role as a Principal Investigator and Investigator of Records for IMPAACT studies at Baylor-Uganda CRS, Korutaro made significant contributions as a Medical Officer in various research projects, including the CHAPAS-3 and RELATES studies. In 2013, she transitioned to a leadership role as the Senior Medical Officer for Research in the CAFGEN study, marking a critical turning point in her career. In 2015, Korutaro was selected as the Clinical Research Site (CRS) Coordinator for the newly joined Baylor-Uganda CRS for the JHU Kampala/Uganda Clinical Trial Unit. In addition to her CRS coordination role, she started her active role as an Investigator for the IMPAACT P1115 study. Her interest and dedication to research led to her selection as the Baylor-Uganda CRS's Investigator of Records for IMPAACT studies, with her leading as the Principal Investigator in several fundamental studies, such as IMPAACT 2009, IMPAACT 2010 (VESTED study) and IMPAACT 2017 (MOCHA study).

Korutaro is an eager learner and has received numerous certifications and specialised training, reflecting her expertise in diverse facets of medical research. Her affiliations with prestigious professional bodies, including the Uganda Medical and Dental Practitioner's Council, her role as a SCORE Manual CHAMPION for DAIDS, and her membership in the Study Coordinator working group of HANC, underscore her esteemed standing in the medical and research community. She is a recipient of the IMPAACT Network 2024 Early Career Investigator Award for a research project titled "Breastmilk Biomarkers of Inflammation, Immune Activation, and Human Milk Oligosaccharides (HMOs) in Women with vs. without Vertical Transmission During Breastfeeding."

Korutaro has also contributed to presentations and scholarly publications. She has co-authored several impactful research papers in prestigious journals, primarily focusing on HIV treatment and prevention.

Korutaro is known for her proficiency in diagnosing and treating tropical diseases and her expertise in HIV/AIDS care. Her adeptness in managing adverse events and her knowledge of epidemiology, health promotion, and research methodologies make her an invaluable asset to research teams."



## **WADZANAI SAMANEKA**

Wadzanai Samaneka is a medical doctor, Clinical Epidemiologist and researcher with over 18 years' experience conducting adult HIV Clinical trials. She is an Adjunct Researcher/Lecturer at the University of Zimbabwe and has been the lead investigator in multiple clinical trials assessing antiretroviral treatment strategies, treatment and prevention strategies for drug susceptible and drug resistant tuberculosis as well as HIV-comorbid conditions like Kaposi Sarcoma and Cryptococcal disease and more recently, monoclonal antibody therapy at ART initiation in sub-Saharan Africa. She has diverse research interests in HIV/AIDS including antiretroviral therapy, prevention, opportunistic infections and long-term complications of HIV/AIDS. Samaneka is passionate about mentoring the next generation of researchers, she has held membership positions within the DAIDS funded ACTG (Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections) network. These include the Tuberculosis Transformative Science Group (TB TSG), Antiretroviral Therapy TSG and the Comorbidities TSG.

Samaneka is currently an active member of the Women's Health Collaborative Science Group (WHCSG). She also serves as a scientific reviewer for the Medical Research Council of Zimbabwe and is a member of the Zimbabwe Ministry of Health TB Working Group.



## **WILLIAM KILEMBE**

William Kilembe is the Centre for Family Health Research in Zambia (CFHRZ) Project Director. He also serves as the Rwanda Zambia Health Research Group (RZHRG) PI, chairperson of the scientific advisory committee and member of the consortium steering committees on the SANTHE network. He leads clinical research on HIV/AIDS, TB and COVID-19 at CFHRZ in Lusaka, Zambia. Kilembe leads epidemiology studies and clinical trials at CFHRZ and his research career has focused on studies that contribute to developing cost effective prevention interventions to address HIV. He has led work on prospective cohort studies of stable heterosexual couples and at-risk women for HIV to understand risk factors for HIV acquisition and has implemented programmes targeting couples that aim at mitigating these risks. Kilembe has also led research studies to understand immune responses to TB and SARS-CoV-2, natural history of COVID-19 and other respiratory viruses and implemented several COVID-19 and HIV vaccine clinical trials. Kilembe's work at CFHRZ contributes to finding cost effective strategies to address public health problems that affect many communities in Zambia and the region.



## **YEUKAI MUSODZA**

Yeukai Musodza is a medical doctor based in Zimbabwe, boasting approximately 10 years of experience in clinical research. With expertise spanning Phase I to IV clinical trials, her professional repertoire includes overseeing trials evaluating broadly neutralising antibodies for HIV prevention, as well as long-acting injectables for HIV prevention. She is also versed in treating HIV within the context of acute infection, along with late-phase clinical trials focused on managing chronic HIV infection and associated co-morbidities such as drug-sensitive and drug-resistant tuberculosis.



## **ZAZA NDHLOVU**

Zaza Ndhlovu works on cellular immune responses to HIV-1, with the ultimate goal of finding a phenotypic target for an HIV vaccine. His research programme includes studies geared towards understanding initial events that contribute to immune dysfunction and subsequent disease progression. He uses excisional lymph node samples from acute and chronic HIV infected patients to interrogate how brief exposure to HIV influences induction and durability of protective immune responses.

Ndhlovu received his PhD in Molecular Microbiology and Immunology from Johns Hopkins University, and did his postdoctoral training at Harvard University. During this time, he studied CD8+ T cell responses in a special group of individuals capable of spontaneous HIV suppression in the absence of antiretroviral therapy – called 'elite controllers'. He made significant discoveries about key features of HIV-specific CD8+ T cell subsets that are able to inhibit viral replication and drive immune escape in elite controllers.

After securing a Faculty position at Harvard University, he decided to relocate his research programme to South Africa. "I reasoned that incidence rates of close to 10% per year in KwaZulu-Natal would enable me to address unique aspects of the host immune response to HIV that could not be undertaken where I had trained, while at the same time I could contribute to scientific capacity building needed to meet current and future African medical challenges," Ndhlovu said. The move brought him to the epicentre of the HIV epidemic and has allowed him access to well pedigreed acute infection samples.

Ndhlovu's academic appointments include member of Faculty at AHRI, Assistant Professor of Medicine at Harvard Medical School and Adjunct Faculty at University of KwaZulu-Natal. He is also an HHMI International Research Scholar.

# LOGISTICS

## **AIR TRAVEL AND GROUND TRANSPORTATION**

For SANTHE-booked air travel, please reach out to [sipho.khumalo@santheafrica.org](mailto:sipho.khumalo@santheafrica.org) if you have any issues. Please note that once your ticket is issued to you, any changes will be at your own cost. For tickets not sponsored by SANTHE, please forward flight details if you would like a Nairobi-airport-to-hotel transfer to be organised for you. A driver with a sign for the Trademark or Tribe Hotel will meet you just outside the airport arrivals area.

## **MEETING VENUE & ACCOMMODATION**

The 2024 ATI Consensus Workshop will be held at the Trademark Hotel, Village Market, Limuru Rd, Nairobi, Kenya, Nairobi, Kenya, (Phone: +254 20 7250000). If SANTHE made your hotel booking, you will have received confirmation of this. All meals that take place outside of the main meeting times can be charged to your room up to a maximum of \$40 per person – if eaten at the hotel's HARVEST Restaurant only (for example if you order room service, this will be for your own account). Please note that alcoholic beverages will not be covered. All other extra costs e.g. phone calls, laundry, etc. are not covered and are to be settled privately with the hotel before departure. For those housed at the Tribe Hotel, please note that the Trademark Hotel is a short walk across the road – reception will help to direct you. Similarly, meals taken outside of the main meeting times, can be charged to your room (if eaten at the HARVEST Restaurant).

## **TRAVEL AUTHORISATION**

All individuals need to apply for travel authorisation in advance of your trip. Please use this link for more information and to apply: <https://www.etakenya.go.ke/ke/en>. All travelers should carry a copy of their e-Travel Authorisation, as this will be requested by officials in Kenya.

## **WEATHER**

Nairobi may experience low temperatures and rain around this time of the year. Please keep a warm and waterproof jacket in your luggage. A reminder that meeting rooms can also sometimes be cold due to excessive air-conditioning, so always keep something extra to wear with you.

## **HEALTH AND SAFETY**

All travelers arriving in Kenya from countries where yellow fever is endemic should present a valid yellow fever certificate. A yellow fever vaccine is recommended for travel to Kenya. Although risk of exposure in Nairobi is low, some countries may request proof of vaccination upon return from Kenya. There is also a very low risk of malaria in Nairobi.

The city is peaceful BUT travelers will always attract unwanted attention from beggars, pickpockets and scammers so be aware, avoid certain areas like Kibera in downtown Nairobi and don't walk around at night (use Uber or ask the hotel which taxis are best). If you're visiting the markets – be assertive or have someone assertive with you – the sellers and their agents can get a little over-zealous.

## **POWER SUPPLY**

In Nairobi power plugs and electrical outlets are type G (British type). Be sure to remember your travel adapter.

## **INTERNET CONNECTION**

The Trademark Hotel will provide complimentary WI-FI.

## **CONTACT DETAILS**

If you have any queries or need assistance, please do not hesitate to contact Sipho (email: [sipho.khumalo@santheafrica.org](mailto:sipho.khumalo@santheafrica.org) || WhatsApp: +27820812747).



**BILL & MELINDA**  
**GATES** *foundation*

**NIH** National Institutes of Health  
 Turning Discovery Into Health